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1 INTRODUCTION 
 
The last decade has seen a vast increase in the development of biomolecules as therapeutic 
agents to treat a wide array of diseases. Various types of bio-drugs (proteins, antibodies, 
nucleotides) investigated in the recent past have entered the late-stage clinical studies but 
almost all that have reached the market, are protein based drugs (Walsh 2010). 
Recombinant insulin for treatment of diabetes was the first biopharmaceutical product to be 
launched in 1982 (Goeddel et al. 1979, Rader 2013).  
 
It was estimated in 2009 that the sales of recombinant therapeutic proteins and monoclonal 
antibodies (mAb) was around 100 billion dollars. This yielded the biopharmaceutical 
market one-sixth the total volume of the 600 billion dollar pharmaceutical industry (Walsh 
2010). Promising data stood out in 2012; seven out of the fifteen top-selling 
pharmaceuticals by revenue were biologicals (FiercePharma 2012). Over 40 % of new 
pharmaceuticals currently being developed are reported to be biopharmaceuticals (Rader 
2013). Over two hundred mAbs and a hundred proteins were reported to be in clinical trials 
(Sheridan 2010). However, the development of protein drugs has been limited by low 
approval rates; for the period between 2006 and 2010, only twenty-five new biological 
entities (NBE) were released in the US and EU market (Walsh 2010) and only four in 2013 
(Kling 2014). Current estimates for protein therapeutics project a growth rate between 7 
and 15% annually for coming years (Walsh 2010). 
 
Therapeutic proteins are endogenous (or engineered proteins closely resembling 
endogenous proteins) and are therefore expected to have better specificity and safety profile 
as compared to the conventional small molecule drugs (Crommelin et al. 2003, Leader et 
al. 2008). The major challenges for developing protein drugs include cost, complex 
manufacturing, relative instability, inadequate pharmacokinetic properties and formulation 
in conventional dosage forms, such as tablets or capsules (Leader et al. 2008, Swami and 
Shahiwala 2013). 
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For most proteins to elicit biological functions, they need to fold and adopt a stable 
conformation, commonly referred to as the native state (Dobson 2004, Tyedmers et al. 
2010). Environmental conditions in vivo are controlled by homeostasis and remain 
relatively stable. This helps proteins maintain their conformational integrity in vivo. 
However, in vitro changes in protein environment such as pH, temperature and ionic 
strength are often of a higher magnitude that might reversibly or irreversibly perturb the 
higher-order protein structure and result in denaturation (partial or complete unfolding from 
the native state). In most cases, unfolding of protein enhances intermolecular interactions 
between polypeptide chains leading to higher order aggregates. In some instances, 
associated tertiary or quaternary structures are considered as aggregates but for the purpose 
of this review, we refer to protein aggregation as a phenomenon that results in clustering of 
proteins and formation of higher order oligomerization with diminished or complete loss of 
biological function. Conformational stability of proteins is of paramount importance for 
biological functionality (Manning et al. 2010). 
 
Although the ability of proteins to form higher order aggregates was initially associated 
with in vivo diseases, it is now acknowledged that this ability is an inherent characteristic of 
proteins (Chiti et al. 2001). Protein aggregates have varying properties. They are either 
soluble or insoluble (Philo 2006), vary in the number of monomers, size, life-time, shape 
and structure (Wang 2005). Apart from severely limiting the efficacy of production and 
manufacturing processes, protein aggregates are known to elicit potentially life threatening 
immunologic responses in vivo (Rosenberg 2006). Thus, from both bioprocessing and 
regulatory perspective, protein aggregation presents a huge challenge. Mechanisms of 
protein aggregation are poorly understood and new analytical tools are being developed for 
their characterization.  
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2 PROTEIN STRUCTURE AND FOLDING 
 
Proteins are composed of polypeptide chains; they follow a sequence of events to acquire 
the biologically active native structural state via a process called ‘protein folding’ (Branden 
and Tooze 1998). Attainment and maintenance of the native structural state is critical for 
biological activity in vivo. Polypeptide chains are composed of twenty different amino 
acids linked to each other via peptide bonds. The chain forms a repeating backbone with 
alternating side-chains of the amino acid residues (Richardson 1981, Branden and Tooze 
1998). The order of amino acids (sequence) as well as the length of the chain (number of 
amino acids) is determined by the genetic code. The sequence of the amino acids in a 
polypeptide chain defines the primary structure of the protein. 
 
As the polypeptide chain gets synthesized, it folds and forms ordered secondary structural 
elements. These are attributed to multiple non-covalent interactions such as hydrogen 
bonds (between polar residues), ionic bonds (between oppositely charged residues) and 
hydrophobic interactions (between non-polar residues). Secondary structural elements 
present in proteins are α-helices, β-sheets, turns and random coils. Multiple secondary 
structural elements are arranged into motifs that pack into compact structural domains 
(Branden and Tooze 1998). The three-dimensional (3D) arrangement of motifs within the 
folding space is referred to as the tertiary structure. It is generally believed that the driving 
force for protein folding is a consequence of the relatively hydrophobic residues trying to 
shield themselves from the aqueous environment (Wang 1999, Levy and Onuchic 2006). 
This so-called ‘hydrophobic collapse’ is postulated to result in the burial of hydrophobic 
residues within the core of protein structure. Polar and charged residues usually decorate 
the surface of the protein, which is solvent exposed.  
 
The interplay between covalent (disulphide bonds between cysteine residues) and non-
covalent interactions stabilizes the tertiary structure of the protein (Branden and Tooze 
1998). In multimeric proteins, the biologically functional unit is composed of a quaternary 
structure formed by oligomerization of the monomeric components.  
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The paradigm of structure-activity relationship is based on the fact that the biological 
function of a protein is a consequence of the three dimensional structure. A partial or 
complete loss of structural integrity might result in loss of activity in vivo. Improper folding 
of proteins is known to cause pathological diseases (Dobson 2004). However, it is 
noteworthy to mention that many biologically active proteins do not possess a structural 
fold in the native state. These proteins are commonly referred to as ‘intrinsically disordered 
proteins’ (IDPs). IDPs have in recent times generated a lot of interest for their physiological 
role (Dyson 2011). This review however, limits its scope to only natively folded proteins 
and not the IDPs. 
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3 IN VIVO PROTEIN AGGREGATION  
 
Many diseases of the central nervous system, such as amyotrophic lateral sclerosis (ALS), 
prion diseases and amyloidoses (Parkinson’s and Alzheimer’s) involve protein misfolding 
and aggregation (Stefani and Dobson, 2003). For example, ALS is associated with 
aggregation of Cu/Zn superoxide dismutase (Stathopulos et al. 2003); transmissible 
spongiform encephalopathies (TSEs) are associated with the prion, a protein which is 
misfolded and aggregates in vivo (Aguzzi and Calella 2009); Parkinson’s disease is 
associated with the aggregation of the α-synuclein protein (Nath et al. 2011) and in 
Alzheimer’s disease, the microtubule associated protein Tau when hyper-phosphorylated 
results in the formation of neurofibrillary tangles (Kfoury et al. 2012). It is not clear 
whether the manifestation of pathological diseases is a direct consequence of the 
aggregation of physiological proteins; nonetheless, aggregation presents a common feature 
in the pathologies of the diseased state. The exact mechanisms of protein aggregation and 
their effects on the organism at the cellular level are not well understood and are subjects of 
intense research (Dobson 2004). Some evidences point to the fact that intracellular protein 
aggregates might impair cellular functions via interactions between exposed hydrophobic 
regions of protein aggregates and cellular proteins or the cell membrane (Stefani and 
Dobson 2003, Tyedmers et al. 2010). 
 
Newly synthesized polypeptide chains experience a high intracellular concentration of 
proteins, commonly referred to as ‘molecular crowding’.  High intracellular concentrations 
might tend to favor aggregation (Dobson 2004, Barral et al. 2004) and be harmful to the 
cellular machinery. To mitigate such adversities, cellular mechanisms have evolved to 
either course correct misfolded/unfolded proteins or degrade them (Stefani and Dobson 
2003).  
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Molecular chaperones, such as heat shock proteins, function by either assisting the correct 
folding of the newly synthesized polypeptide chain or by blocking incorrect folding 
pathways. Some chaperones are known to be able to rescue proteins from aggregates 
(Barral et al. 2004, Tyedmers et al. 2010). The formation and sequestration of intracellular 
protein aggregate deposits is considered to be a next-in-line response in protecting the 
cellular machinery from harmful effects of the aggregates. (Tyedmers et al. 2010). 
Aggregation of proteins in vivo is often a part of the cellular response to an imbalance in 
protein homeostasis – cell’s own ‘quality control’ process. We appreciate and understand 
the importance of protein aggregation in vivo but to limit the scope of this review, we 
discuss here in vitro protein aggregation that has more direct relevance in the context of 
biopharmaceutical development. 
 
 
4 AGGREGATION OF THERAPEUTIC PROTEINS 
 
Therapeutic proteins are produced recombinantly in expression systems and the 
environmental conditions that the protein experiences in its journey from synthesis to 
purification are very different from those in vivo. The protein is exposed to environmental 
stresses both physical and chemical in nature that can affect the stability of the native state. 
Both the physical and chemical factors can perturb the tertiary structure of the protein and 
result in unfolding of the polypeptide chain. Unfolding of proteins is believed to be one 
major cause of aggregation. The physical instability is brought about by changes in 
conditions and external factors such as temperature, shear stresses, pressure etc. (Wang 
2005). Chemically induced changes and degradation of the protein structure are caused by 
factors such as oxidation, deamidation, acylation and peptide bond hydrolysis (Crommelin 
et al. 2003).  
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The propensity of a protein to undergo aggregation is dependent on the inherent properties 
of the protein, namely its sequence and structure (Pawar et al. 2005, Tartaglia et al. 2008). 
This hypothesis is supported by the fact that in certain cases, even point mutations are 
known to significantly influence the aggregation propensity of a protein (Fink 1998, Chiti 
et al. 2002, Stathopulos et al. 2003). Also, it has been observed that β-sheet structured 
proteins are more prone to aggregation than α-helical proteins. Many protein aggregates 
have diminished α-helix content and an increased β-sheet content as compared to the native 
structure (Wang 2005, Laurence and Middaugh 2010). However, not all proteins with high 
β-sheet content have the propensity to aggregate. Conformational changes causing 
transition from α-helices to β-sheets might enhance the propensity to aggregate (Chiti et al. 
2002). Conversely, in certain cases, transitions from β-sheets to α-helices might result in 
increased stability (Villegas et al. 2000). 
  
Strategies to prevent protein aggregation in formulations present a significant challenge for 
biopharmaceutical development. The approach in general, is to find conditions that would 
stabilize the native state or destabilize the unfolded state. This can be achieved by adding 
excipients, chemical modifications to the protein or by recoding the genetic sequence to 
remove aggregation prone regions in the protein. 
 
4.1 Pathways and mechanisms of protein aggregation 
 
Protein aggregates may consist of native protein monomers or completely unfolded 
proteins, although a growing body of evidence supports the idea that intermediates between 
native and completely unfolded structures serve as precursors to protein aggregates (Fink 
1998, Dobson 2004). These intermediates can be envisioned as partially unfolded proteins 
with exposed aggregation-prone regions that can interact with corresponding regions of 
other proteins. 
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Protein folding and aggregation can take place by different pathways (Figure 1). Aggregate 
formation is not exclusive and can occur via different mechanisms simultaneously (Wang 
2005; Philo and Arakawa 2009). The presence of aggregates in a therapeutic protein sample 
and importantly, the amount and type of aggregates present might change with time 
depending on the kinetics of association and dissociation. It has been observed that for slow 
processes, it might take several hours or even days to equilibrate after a perturbation in 
protein conditions (Philo 2003). On the other hand, some aggregates are transient and have 
a relatively short life-time (Philo 2006). The types of aggregates formed depend on the 
mechanism and pathway of aggregation (Tyedmers et al. 2010). Understanding the 
phenomenon of aggregation is thus of fundamental importance to develop rationale for its 
inhibition; a major challenge in biopharmaceutical development. 
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Figure 1: Protein folding, degradation and aggregation pathways.  
Adapted, with permission, from Dobson © (2003) Macmillan Publishers Ltd. 
 
Protein aggregates are often categorized based on properties of reversibility and 
irreversibility. However, irreversibility doesn’t necessarily mean a permanent change; 
perturbations in environmental conditions (e.g., pH, temperature) may alter an irreversible 
aggregate into a reversible one (Philo 2006). In the same logic, terminologies such as 
soluble or insoluble aggregates might be misleading. The nomenclature used in the field of 
protein aggregation varies widely and terminologies are often used interchangeably by 
research groups. Efforts are being directed to harmonize the use of terms regarding protein 
aggregates (Narhi et al. 2012). 
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Factors leading to protein aggregation include but are not limited to: changes in protein 
concentration, pH and temperature and different processing steps involving mechanical 
stress caused for instance by stirring, shaking, pumping and freeze/thaw cycles (Wang 
2005, Mahler et al. 2009). To which extent each factor affects the rate of formation and the 
type of aggregates formed differs. These factors and their effects on protein aggregation are 
discussed in Section 4.4. 
 
4.1.1 Covalent aggregates 
 
Structural modifications induced by chemical changes such as deamidation, transamidation 
(Strickley and Anderson 1997) and oxidation of amino acid residues such as histidine 
(Khossravi et al. 2000) arginine, lysine, methionine, and proline (Stadtman 1993). Changes 
in chemical structure of a protein alter the electronic charges that can potentially influence 
the attractive or repulsive forces between residues of protein monomers and/or expose 
create novel regions capable of interacting with other surfaces and forming aggregates. 
 
Covalent disulphide bonds between cysteine residues stabilize protein structure. However, 
presence of unpaired cysteine residues also makes them susceptible to form intermolecular 
disulphide bonds between polypeptide chains and aggregate (Yoshioka 1993, Trivedi et al. 
2009, Brych et al. 2010). Non-native disulphide bonds are believed to stabilize intermediate 
states of aggregation. Tyrosine residues are also known to undergo oxidation to form 
covalent dityrosine bonds (Malencik and Anderson 2003). Covalent aggregates are 
generally irreversible in nature. 
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4.1.2 Non-covalent aggregates 
 
Native protein monomers may associate with each other by virtue of weak non-covalent 
interactions such as, hydrogen bonds, ionic bonds and hydrophobic interactions. Self-
complementary regions of a protein are therefore prone to aggregation (Figure 2a) 
Aggregation via this pathway (intermolecular association) is a function of the protein 
concentration; higher concentrations likely result in more encounters between the 
monomers that enhance association. The size of such aggregates also tends to increase over 
time (Philo and Arakawa 2009). Insulin monomers are known to associate and form 
hexamers inside the pancreas (Xu et al. 2012, Bryant et al. 1993). The hexamers 
subsequently dissociate into dimers in the blood stream and finally into monomers (Dobson 
and Steiner 1998). The different oligomeric states of insulin do not affect the bioactivity or 
immunogenicity of insulin as long as dissociation of the multimer takes place. However, 
the pharmacokinetic profile varies for the different oligomers and this has been utilized to 
engineer new insulin-products with desired pharmacokinetics and half-life (Crasto et al. 
2009, Danne and Bolinder 2012). 
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(a) 
 
 
(d) 
 
(b) 
 
 
(e)  
 
(c) 
 
Figure 1: General mechanisms of protein aggregation.  
Adapted, with permission, from Philo and Arakawa © (2009) Bentham Science Publishers 
Ltd. 
 
In a related mechanism, although the native monomer does not self-associate but partial 
unfolding or a conformational change from the native state might expose regions of the 
protein that are prone to associate (Figure 2b). The perturbation in structure can be caused 
by external stress, commonly encountered in the different manufacturing and processing 
steps. Exposed regions might also be susceptible to chemical changes enhancing 
aggregation (Figure 2c) (Wang 2005). 
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Protein aggregation can be triggered by a contaminant or an impurity present in the sample 
(Figure 2d). Usually, such contaminants are derived from manufacturing and storage 
processes. Examples include, steel particles (Tyagi et al. 2009) tungsten, rubber (Sharma 
2007), silica (Chi et al. 2005), particles from syringe filters (Liu et al. 2012) and silicone 
oil droplets (Majumdar et al. 2011). Such foreign particles usually act as nucleation seeds 
(Philo 2009), for aggregation. The nucleus grows in size as more protein molecules 
associate.  Such a process of aggregation is often termed as heterogeneous nucleation and 
reinforces the importance of avoiding foreign particles/contaminants in protein 
formulations. Protein aggregates formed via other mechanisms may also act as nuclei to 
promote aggregation by this mechanism (Andrews et al. 2008, Kiese et al. 2010) but 
referred to as homogenous nucleation. Aggregation via this mechanism typically results in 
visible particles or precipitates as the large aggregates associate (Speed et al. 1997). 
Characteristic to this mechanism also is that at an early phase aggregates are virtually 
undetectable, but then rather suddenly large aggregates are present and accumulate (Chi et 
al. 2003, Philo and Arakawa 2009). The lag-phase associated with the nuclei based 
aggregation is due to an energy barrier; the initial rate of aggregation around the nucleation 
seed is slow but after a critical size has been reached, aggregation takes place rapidly. 
Formulation strategies are targeted towards influencing the lag phase to minimize 
aggregation e.g., alteration of the formulation’s viscosity to decrease diffusion. Apart from 
foreign particles and previously formed aggregates acting as nucleation seeds in 
aggregation process, the interfaces and surfaces with which the proteins have contact also 
affect aggregation (Figure 2e). For instance, polystyrene (Smith et al. 2007), air-water 
interface (Bee et al. 2011), stainless steel surfaces (Bee et al. 2010) and ice-water interface 
(Kueltzo et al. 2008) have shown to induce aggregation in proteins. The contacts between 
protein and surfaces / interfaces are mediated by hydrophobic and electrostatic interactions 
that might result in binding of the protein followed by conformational changes of the native 
structure (Philo and Arakawa 2009). The conformational change increases the protein’s 
propensity to aggregate.  
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4.2 External factors affecting protein aggregation 
 
Environmental factors and conditions have a key role in protein stability. Identification and 
understanding their mechanism of action in protein stability is crucial towards developing 
rational approaches for inhibition of aggregation. Although each factor influences the 
stability of the protein, it is the interplay of the different factors that ultimately affect the 
conformational state of the protein. Some common factors that affect protein stability and 
aggregation propensity are discussed below. Some of the most common factors that 
influence protein aggregation and methods to inhibit them are discussed below.  
 
4.2.1 Protein concentration 
 
Concentration of protein is a significant factor in its aggregation. Higher protein 
concentrations enhance intermolecular protein - protein interactions that can potentially 
initiate the process of aggregation (Saluja and Kalonia 2008). It appears that for certain 
mechanisms, a minimal threshold concentration might be necessary for the initiation of 
aggregation (Wang 2005). Conversely, cases where high concentration of protein results in 
associates that are less prone to aggregation (Saluja and Kalonia 2008), high protein 
concentrations might not enhance aggregation propensity.  
 
Protein therapeutics is most commonly formulated as solutions intended for parenteral 
administration (e.g., subcutaneous injections) since, other more conventional (oral) dosage 
forms are unsuitable due to enzymatic degradation and limited permeability across the 
gastro-intestinal epithelium (Frokjaer and Otzen 2005). Therapeutic formulations are often 
necessary to be of high concentrations to achieve high doses and at the same time limit the 
injection volumes (Shire et al. 2004, Frokjaer and Otzen 2005). Thus, even though having a 
low concentration of protein in formulations seems to be an easy solution (Shiraki et al. 
2002) to mitigate aggregation related issues, practical requirements for clinical use limits its 
applicability. 
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4.2.2 Solution pH 
 
Proteins are stable (retain native conformation) within a narrow range of pH, characteristic 
to each individual protein. Outside the optimal pH range, proteins might undergo 
transitions from native conformation, unfold and eventually aggregate (Chi et al. 2003). 
Changes in pH redistribute the charges in protein that can affect the attractive or repulsive 
interactions between molecules. During bioprocessing, a therapeutic protein may encounter 
changes in solution pH that can adversely affect its stability (Wang 2005). For instance, 
aggregation of partially unfolded monoclonal IgG was observed after a brief exposure to 
low pH (Filipe et al. 2012).  
 
4.2.3 Temperature 
 
Proteins retain stability below a critical temperature that is characteristic to each protein. 
Above the critical temperature, proteins might undergo structural unfolding making them 
susceptible to aggregation (Speed et al. 1997, Mahler et al. 2009). For example, thermal 
stress has been observed to result in the formation of small soluble monoclonal IgG1 
aggregates (Hawe et al. 2009). 
 
An increase in temperature results in higher reaction rates and the frequency of 
intermolecular collisions increase with temperature. Consequently, proteins are known to 
aggregate at higher temperatures (Weiss IV et al. 2008, Mahler et al. 2009). Conversely, 
low temperatures can also affect the aggregation behavior of proteins, a phenomenon 
known as ‘cold denaturation’.   
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To avoid aggregation caused by increase in temperature during manufacturing and 
processing, care must be taken to avoid working temperatures above the melting 
temperature (Tm). Tm is defined as the temperature at which 50 % population of the protein 
is unfolded and is typically between 40° and 80° C for most proteins (Wang 1999). It is 
preferable to have operational temperatures well below Tm, typically between 2 - 8° C 
(Mahler et al. 2009). In certain cases, amino acids as excipients have shown to prevent 
temperature-induced aggregation (Wang 1999, Shiraki et al. 2002). 
 
4.2.4 Foreign particles and container materials 
 
Contaminants and particles present in a protein solution may serve as nucleation seed and 
induce aggregation. Binding of proteins to particles and surfaces can be reversible or 
irreversible and is mediated by forces such as, electrostatic and hydrophobic interactions 
(Bee et al. 2010, Bee et al. 2011). Adsorption of proteins onto different surfaces may also 
denature and unfold proteins (partially or completely) to cause aggregation (Manning et al. 
2010, Bee et al. 2011). For instance, monoclonal IgG2 absorbs onto surfaces like Teflon™ 
during the process of freeze thawing (Kueltzo et al. 2008).  
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In certain cases, the container material, its closure and stoppers is not a direct cause of 
protein aggregation but a brief exposure to other interfaces, surfaces and / or particles 
during processing steps, storage and delivery might be sufficient to initiate aggregation 
(Bee et al. 2011, Liu et al. 2012). For example, a leachable such as, Fe ions from steel, can 
act as a nucleation seed and also cause aggregation by oxidation (Lam et al. 1997). The 
phenomenon of leaching seems to be influenced by the properties of the solution. Stainless 
steel surface was reported to induce aggregation in a mAb and  increase the amount of 
carbonylated degradation products (Bee et al. 2010). Shedding of stainless steel 
nanoparticles from piston pump contributed to heterogeneous nucleation of an IgG (Tyagi 
et al. 2009). Silicone oil, a coating frequently present on the surface of prefilled syringes 
commonly used with protein therapeutics, is also known to induce aggregation in many 
proteins (Jones et al. 2005, Majumdar et al. 2011). Similarly, microparticles and 
nanoparticles shed from syringe filters have been reported to stimulate particulate 
formation and aggregation of keratinocyte growth factor 2 (KGF-2) especially, under 
conditions of agitation (Liu et al. 2012). This observation assumes immense significance 
and concern as the very filters that are used to remove aggregates actually contribute to the 
process of aggregation.  
 
Modifications to formulation and manufacturing processes or materials associated with 
equipment and containers are usually seen as methods to inhibit or slow aggregation caused 
by surfaces or foreign particles (Jones et al. 2005, Bee et al. 2011). For instance, the use of 
BD-42 (BD Technologies) coating inside prefilled syringes instead of silicone oil has been 
proposed for silicone-sensitive proteins (Majumdar et al. 2011). The use of surfactants has 
also been successfully utilized; polysorbate 20 suppressed aggregation of IgG1 caused by 
stainless steel microparticles (Bee et al. 2010). Removal of foreign particulates suppressed 
heterogeneous nucleation and delayed aggregate formation in the formulation of 
recombinant human platelet-activating factor acetylhydrolase (Chi et al. 2005). 
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4.3 Detection and characterization of protein aggregates 
 
Presence of protein aggregates in therapeutic protein formulations can be a serious threat to 
the efficacy and safety of the product. Protein aggregates are known to elicit immunogenic 
response that can be fatal. Regulatory guidelines regarding particles in dosage forms 
intended for injection in general have been made by the U.S. Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA). The U.S. 
pharmacopoeia sets limit for acceptable amounts of visible and sub-visible particles in 
parenteral injections. However, acceptable levels of sub-visible and soluble particles (small 
sized protein aggregates, dimers etc.) are poorly defined and general consensus is still being 
evolved in this area of active research (Cromwell et al. 2006, Carpenter et al. 2009, Mahler 
et al. 2009, Singh et al. 2010). 
 
In adherence to regulatory guidelines and guarantee the safe use of protein drugs, detection 
and characterization of protein aggregates is an absolute necessity. Apart from safeguarding 
regulatory interests, such efforts also help detect and investigate mechanisms of 
aggregation at each processing step and consequently in devising strategies to inhibit 
aggregation. 
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The methods used to characterize protein aggregates are wide and diverse; from simple 
visual inspection to sophisticated analytical methods that require expertise (den Engelsman 
et al. 2011). No single method is sufficient as the nature and size of aggregates influence 
the choice of analytical technique (Mahler et al. 2009, den Engelsman et al. 2011). 
Furthermore, each method is able to assess only a certain aspect of the protein aggregate, 
for instance aggregate size, morphology, aggregate concentration etc. The transient nature 
of the aggregates contributes to the complexity of characterization as the life-time of 
aggregates ranges from milliseconds to even days in the life-cycle of a protein therapeutic. 
The complexity is further compounded by the fact that the analytical method could itself 
interfere in the aggregation process and create artifacts (Philo 2006, Mahler et al. 2009). 
Current approaches utilize orthogonal methods to characterize protein aggregates (Philo 
2006; den Engelsman et al. 2011). The use of orthogonal methods for similar sized 
particles might be useful in comparing different methods and optimization (Mahler et al. 
2009). 
 
Analytical tools used to detect and characterize protein aggregates can be broadly 
categorized as chromatographic, electrophoretic, light scattering, microscopic and 
spectroscopic methods (den Engelsman et al. 2011). The methods differ from each other in 
detection principles, detection size range and time needed for the analysis. Some methods 
are better suited for quality control (QC) purposes and others for more extensive 
characterization purposes. Some of the most commonly utilized methods for detection and 
characterization of protein aggregates are discussed in following sections. 
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4.3.1 Size exclusion chromatography 
 
Size exclusion chromatography (SEC), also known as gel filtration, is one of the most 
popular analytical methods in quantifying and sizing protein aggregates (Mahler et al. 
2009). Particles and aggregates of different sizes are separated on a column matrix based on 
their differential ability to enter and remain inside small pores and cavities of the matrix, 
dictated by the size of the particles or molecules (den Englesmann et al. 2011). Large 
aggregates cannot enter the pores to the same extent as small aggregates; consequently, 
their presence is limited to the outer volume of the column and they traverse shorter 
distance as compared to the smaller sized particles / molecules. The larger sized particles / 
molecular entities are thus eluted out first from the column. Medium-sized molecular 
entities can enter the pores to a limited extent and are retained inside the column longer 
than large aggregates but are still eluted out before smaller entities. The elution time / 
volume is monitored by measuring absorbance. The method allows sizing and quantitation 
of protein aggregates based on peak areas (Mahler et al. 2009). However, the accuracy of 
SEC in quantitation of aggregates can give rise to artifacts due to adsorption of proteins to 
the column matrix (Gabrielson et al. 2007). 
 
Advantages in using SEC for protein aggregate analysis include relatively fast analysis and 
high sample throughput due to automation and high sensitivity (Carpenter et al. 2010, Zölls 
et al. 2012). Typically, small sample volumes are needed for SEC (den Engelsmann et al. 
2011).  
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SEC can however be limited in its application primarily due to requirements in sample 
preparation. Larger insoluble aggregates cannot be applied to SEC and need to be filtered 
out during sample preparation (Mahler et al. 2009). High molecular weight oligomeric 
species might accumulate on the column or elute in the void volume (Zölls et al. 2012) and 
thus be overlooked in the analysis. These larger particles can also degrade the column over 
time and affect its performance adversely (den Engelsmann et al. 2011). Protein shape 
affects the accuracy of SEC analysis and correlations between elution volume / time with 
molecular weight might result in erroneous interpretation (Mahler et al. 2009). Dynamic 
ranges of SEC columns are also rather limited (Mahler et al. 2009); a column that results in 
a good separation between a monomer and a dimer may fail to resolve between a trimer and 
larger aggregates. 
 
Buffer conditions during SEC might dissociate some aggregates and thus influence 
adversely the characterization of protein sample (Ahrer et al. 2003, Carpenter et al. 2009, 
den Engelsmann et al. 2011). Analyte properties may also be altered due to interactions 
with the matrix (Zölls et al. 2012). Adsorption of protein monomers and aggregates onto 
the column matrix is also a major concern (Carpenter et al 2010). Formation of protein 
aggregates during the process of SEC has also been observed (Philo 2006). Due to these 
limitations, SEC is generally used in conjecture with other orthogonal methods to validate 
the quality of protein therapeutics (Philo 2006, Carpenter et al. 2010).  
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4.3.2 Dynamic light scattering 
 
Dynamic light scattering (DLS), also known as quasi-elastic light scattering (QELS) and 
photon correlation spectroscopy (PCS), was discovered in the 1950’s, which measures the 
light-scattering intensity fluctuations caused by Brownian motion of particles in solution 
(Gun’ko et al. 2003, Li et al. 2011). This is influenced by hydrodynamic radius (rh) of the 
particles, a characteristic feature dependent on the particle’s mass and shape (Philo 2009). 
The method is non-destructive and requires minimal amounts of sample and thus suits very 
well early stage diagnostics on protein aggregation with limited sample availability (den 
Engelsman et al. 2011). Also, the components of the sample do not need to be separated. 
DLS is capable to detect both reversible and irreversible aggregates (Philo 2009). 
 
Although DLS presents a versatile analytical tool to characterize protein aggregates, it does 
have certain limitations. It does not provide quantitative but only qualitative estimates (den 
Engelsman et al. 2011). Non-spherical particles are treated as spheres in estimations of 
hydrodynamic radii (Philo 2009). In principal, the size of an aggregate can be measured 
with DLS but when characterizing a polydisperse solution containing aggregates of varying 
sizes (which is often the case), the absolute sizes reported are inaccurate and lack precision 
(Ahrer et al. 2003, Philo 2009). The method is also inherently rather poor in resolution and 
not well suited for characterization of small oligomers as the signal intensity (proportional 
to the sixth power of diameter as due to the Rayleigh law) is weighted in favor of larger 
molecular species  (Li et al. 2011). DLS also suffers from inability to distinguish between 
the identities of similar sized particles (Philo 2006). Ideally, DLS is best suited for rapid 
screening of large aggregates and particles in low concentration solutions (Philo 2009). 
DLS has been utilized in the detection of bovine serum albumin (BSA) and human serum 
albumin (HSA) aggregates (Jachimska et al. 2008), soluble aggregates of recombinant 
human factor VIII (Grillo et al. 2001), and aggregates in human IgG samples (Ahrer et al. 
2003) in biopharmaceutical formulations. 
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4.3.3 Analytical ultracentrifugation 
 
Analytical ultracentrifugation (AUC) is an analytical method based on differing 
sedimentation characteristics between molecules of varying sizes during high-speed 
centrifugation (Philo 2009). The sedimentation follows Stokes’ law and the sedimentation 
velocity of any particle depends on sedimentation coefficient, a parameter dependent on 
molecular mass, size and shape of the particle, viscosity of the fluid and the density 
difference between the particle and the fluid (Philo 2009, Zölls et al. 2012). Two different 
methods are most often followed: sedimentation velocity (SV), for measuring protein size 
and shape (Liu et al. 2006, Mahler et al. 2009) and sedimentation equilibrium (SE), for 
determination of protein quaternary structure (Philo 2003) and mass (Mahler et al. 2009). 
SV is more commonly utilized in protein aggregate studies and the term is often used 
interchangeably with AUC (Philo 2009). 
 
In SV, the sample(s) are spun at very high speeds for 2 - 4 hours to separate the particles 
based on differing sedimentation velocities (Philo 2003). The data is analyzed with 
different data analysis programs (Berkowitz 2006, Liu et al. 2006). In SE, the sample(s) are 
conversely spun at low speeds and the centrifugal force pushes the particles outwards. 
Increase in concentration is opposed by diffusion of the particles resulting in an equilibrium 
distribution inside the centrifugal cell based on particulate mass (Philo 2003). 
 
AUC is advantageous for investigating protein aggregation as no sample preparation other 
than dilution is often necessary and the solution protein formulation can often be used as a 
sample directly (Berkowitz 2006, Arthur et al. 2009). Multiple samples (e.g., protein in 
different formulation buffers) can be analyzed in parallel (Berkowitz 2006). A wide range 
of particle masses and sizes can be analyzed using AUC by altering the centrifugation 
velocity. This approach is useful for polydisperse solutions. Both, SV and SE are based on 
physical principles and do not require protein standards for calibration. AUC allows 
comparison of data acquired years apart and this makes it an attractive method for studies 
on long-term quality assessment and stability of protein samples (Philo 2003). 
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The ability to detect aggregates present in low concentrations is critical and failure to do so 
might mean that some aggregates remain unaccounted for in a sample. This might result in 
potential artifacts in data analysis (Gabrielson et al. 2009). Both, the limit of detection 
(LOD) and limit of quantitation (LOQ), are relatively high for SE, especially for certain 
types of protein aggregates (Philo 2009). Due to the relatively long experimental run time, 
AUC might fail to detect aggregates of transient nature (Philo 2006). AUC also suffers of 
rather poor sensitivity towards smaller aggregates and also of poor reproducibility as the 
phenomenon of sedimentation is a consequence of interplay between several factors that 
cause considerable variation (Philo 2009). For instance, misalignment of the centrifugal cell 
was found to be a major contributor to variability in the analysis of an antibody (Arthur et 
al. 2009). Sedimentation of excipients in protein formulation are known to produce 
gradients of density and viscosity that might affect the sedimentation of protein aggregates 
significantly and hinder their detection (Philo 2009). For example, 5% sorbitol was shown 
to mask the presence of low concentration of mAb aggregates during SV due to co-
sedimentation of sorbitol (Gabrielson et al. 2009). The quality of the centerpieces and cell 
holders can also affect the precision and accuracy of the measurements and requires regular 
inspection of the integrity of such parts (Pekar and Sukumar 2007). 
 
Despite certain limitations, AUC remains a powerful tool for detection and characterization 
of protein aggregates. It can be used orthogonally to validate and complement other 
analytical methods (Liu et al. 2006, den Engelsmann et al. 2011) and also in development 
of more accurate SEC methodology (Berkowitz 2006). 
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4.3.4 Asymmetrical flow field flow fractionation 
 
Different field flow fractionation (FFF) methods have been developed for analytical 
purposes (Mahler et al. 2009). Of these, asymmetrical flow field flow fractionation (AF4) 
is most commonly utilized to study protein aggregation due to its ability to separate protein 
aggregates. As in SEC and SV-AUC, the separation of protein aggregates in AF4 is based 
on differences in hydrodynamic radii. Separation occurs in an asymmetrical thin channel 
into which the sample is injected and the molecular species are transported along by a 
laminarily flowing mobile phase (Fraunhofer and Winter 2004). A perpendicular cross-flow 
to the laminar flow directs the analytes towards a semipermeable membrane that is 
impermeable to analytes. The smaller particles as compared to the larger ones, diffuse 
readily back to the laminar flow and are eluted from the flow channel before the larger 
particles. The eluted particles are characterized using various detectors (den Engelsmann et 
al. 2011). 
 
AF4 lacks a stationary phase and this mitigates problems caused by interactions of the 
stationary phase with aggregates. Also, shear-sensitive analytes can be analyzed 
(Fraunhofer and Winter 2004). The sample volumes needed are typically low (Zölls et al. 
2012) and protein formulations can be applied directly without much sample preparation 
(Liu et al. 2006). Even though protein molecules’ propensity to aggregate can be influenced 
due to interactions with the membrane, this can often be mitigated by reducing the cross-
flow and by the choice of a low absorption membrane (Liu et al. 2006) or by the addition of 
surfactants (Fraunhofer and Winter 2004). 
 
One of the main drawbacks of AF4 is the need for tedious method development to obtain 
good separations and results as the methodology is still evolving and not developed like 
other methods such as, SEC (den Engelsmann et al. 2011). Since the separation is 
dependent on multiple factors, the method development process needs extensive 
optimization (Zölls et al. 2012). Changes in concentrations during the analysis might also 
have an impact on the estimation of aggregates present (Mahler et al. 2009). 
26 
 
 
FFF methods are best suited for analysis of large aggregates (Hawe et al. 2012) that would 
otherwise be difficult to detect by AUC due to sedimentation and by SEC due to removal 
by filtration during sample preparation (Liu et al. 2006). A wide range of particle size (1 
nm - 100 µm) can be analyzed by AF4 by tuning the rate of cross-flow (Fraunhofer and 
Winter 2004). The dynamic size range makes AF4 a robust analytical tool in detection and 
characterization of protein aggregates. A stressed IgG formulation containing a large 
proportion of submicron aggregates was used for AF4 method development that 
successfully detected submicron aggregates of another IgG and etanercept, a fusion protein 
used as an anti-tumor necrosis factor (anti-TNF) (Hawe et al. 2012). 
 
4.3.5 Spectroscopy and other methods 
 
Apart from the methods discussed above to study protein aggregation, several other 
methods exist and are being developed to address emerging challenges in studying protein 
aggregation. For example, early detection of antibody A and human calcitonin aggregates 
was reported with fluorescence microscopy after staining with Nile Red – a dye that binds 
to hydrophobic regions in proteins and protein aggregates, and also proposed as a method 
for early detection of changes in protein formulations as sample preparation is unnecessary 
(Demeule et al. 2007). Trastuzumab aggregates caused by the addition of 5% dextrose were 
detected and characterized with fluorescence spectroscopy and transmission electron 
microscopy (TEM) (Demeule et al. 2009). Application of mass spectrometry in protein 
aggregation studies has proved to be challenging due to instrument bias caused by 
ionization. However, electrospray ionization mass spectrometry (ESI MS); a method that 
utilizes a ‘soft’ ionization step, has been reported in characterizing aggregates of 
recombinant human antithrombin III (Wang et al. 2012). In addition, the use of commonly 
used methods such as sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE), capillary electrophoresis-SDS, circular dichroism (CD) spectroscopy and nuclear 
magnetic resonance (NMR) spectroscopy has also been reported for studies on protein 
aggregation (Mahler et al. 2009, den Engelsmann et al. 2011, Zölls et al. 2012). 
27 
 
 
4.4 Control of protein aggregation  
 
Therapeutic proteins undergo several environmental and stress factors throughout their life 
cycle: expression in cell cultures to purification, formulation and in vivo administration 
(Manning et al. 2010). The most commonly encountered environmental factors are changes 
in protein concentration, pH, temperature, ionic strength as well as shear stresses, freeze 
drying related stress and exposure to different interfaces (Wang 2005, Cromwell et al. 
2006). Environmental factors influence protein stability and proneness to aggregation; 
although a single processing step may not result in an aggregate per se, it can result in a 
precursor for aggregation that is more likely to aggregate in further processing steps. Apart 
from these factors, higher order aggregates can be formed even in the native conformational 
state of proteins (Chi et al. 2003). 
 
Generally, aggregation of therapeutic proteins is viewed as a major challenge in vitro for 
production, formulation and storage. However, aggregation might also potentially take 
place in vivo after administration (Frokjaer and Otzen 2005, Mahler et al. 2010a). For 
instance, when administered subcutaneously, the molecules are initially localized to a 
relatively small area resulting in high concentrations. In combination with changes in 
environmental factors, this could potentially cause aggregation.  
 
The following sections highlight the issue of protein aggregation at different stages in the 
life cycle of protein therapeutics and discuss means to effectively mitigate this challenge. 
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4.4.1 In silico assessment of protein aggregation 
 
Computational methods, such as in silico molecular simulation (Bratko et al. 2007) are 
being used and developed to predict the propensity for aggregation of a given protein 
sequence. Models and algorithms derived from computational methods identify sequences 
and motifs that are prone to aggregation (Tartaglia et al. 2008, Agrawal et al. 2011, 
Roughton et al. 2013). Even though the computational models are simplistic (Bratko et al. 
2007, Cellmer et al. 2007) and cannot predict de novo aggregation of a given protein, they 
are useful in understanding mechanisms, precursors and inducers of aggregation. Recent 
efforts are being directed to utilize computational tools at an early stage of drug 
development to identify promising protein molecules (Agrawal et al. 2011). Proteins with 
desirable conformational stability and aggregation propensity can be screened relatively 
rapidly using in silico methods (Agrawal et al. 2011). Such an approach has the potential to 
reduce the number of experiments and aid in the design of formulation screening with 
preferable excipients (Cellmer et al. 2007, Roughton et al. 2013).  
 
4.4.2 Protein expression 
 
Prokaryotic and eukaryotic expression systems are utilized to produce recombinant 
therapeutic proteins. Eukaryotic expression systems are mostly suited for producing 
therapeutic proteins of interest since they offer post-translational modifications. However 
the bacterial expression system remains an attractive option due to rapid growth, easy 
culture conditions and overall cost-effectiveness (Sørensen and Mortensen 2005).  
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Bacterial expression systems, such as E. coli, are however, limited by their inability to 
carry out post-translational modifications or disulphide bond formation.  This tends to 
hinder proper folding of the polypeptide chain and results in the formation of non-
functional proteinaceous granules (inclusion bodies) inside the bacterial cytoplasm 
(Villaverde and Carrió 2003, Singh and Panda 2005). Recovery of the recombinant protein 
in its native conformational state from inclusion bodies requires solubilization under 
denaturing conditions and refolding (Sørensen and Mortensen 2005). 
 
To achieve soluble expression of recombinant proteins, several approaches have shown 
promise. Preconditioning of cells with a complex growth media  (Hoffmann et al. 2004); 
tuning of expression conditions such as, temperature (Vasina & Baneyx 1997, 
Hammarström et al. 2002, Vera et al. 2007), induction conditions (Bentley and Kompala 
1990, Galloway et al. 2003, Studier 2005, Tu et al. 2009, San-Miguel et al. 2013), 
expression rate (Galloway et al. 2003, Vera et al. 2007); co-expression of molecular 
chaperones – proteins that aid folding – (de Marco et al. 2004, Kim et al. 2005, de Marco et 
al. 2007) and fusion with soluble protein / peptide tags (Lichty et al. 2005, Waugh 2005, 
Esposito and Chatterjee 2006, Bird 2011). Refolding from inclusion bodies can be achieved 
by solubilizing them in a denaturant (GdHCl) and subsequent gradual removal of 
chaotropic reagents (Singh and Panda 2005). Arginine is known to assist refolding of 
recombinant proteins from inclusion bodies (Arakawa and Tsumoto 2003). Immobilized 
molecular chaperones in vitro have been successful in refolding from inclusion bodies 
(Rudolph and Lilie 1996, Altamirano et al. 1997, Gao et al. 2003, Jhamb et al. 2008). 
Engineered strains of E. coli have also been utilized to express soluble proteins (Miroux 
and Walker 1996, Sørensen and Mortensen 2005, Berrow et al. 2006).  
 
Soluble expression of proteins is an extensive field of research and a detailed discussion on 
this topic is beyond the scope of this review. Several excellent treatises (Jonasson et al. 
2002, Sørensen and Mortensen 2005, Peti and Page 2007, Sahdev et al. 2008) exist on this 
subject for the interested reader.  
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4.4.3 Purification 
 
A protein therapeutic must be absolutely pure and free from impurities for both efficacy 
and safety concerns. After the expression of the recombinant protein, the protein is purified 
by chromatographic methods (Cromwell et al. 2006). Such a process generally involves 
several steps, each utilizing differences in physicochemical properties of the protein of 
interest from others. 
 
Although the aim of purification is to remove impurities such as, viruses, other host 
organism proteins and protein aggregates from the protein of interest, protein aggregation 
can occur during the process of purification (Wang et al. 2005). Varying conditions of pH, 
concentration and ionic strength could potentially induce aggregation. For instance, during 
affinity chromatography with protein A, conditions for elution at low pH might induce 
aggregation. This was indeed observed in the case of IgM (Phillips et al. 2001) and Fc 
fusion protein (Shukla et al. 2007). However, interactions between the protein and protein 
A might also be a cause of aggregation. 
 
Optimization of the purification methodology with different buffer systems and process 
parameters can help minimize protein aggregation during purification (Cromwell et al. 
2006). A decrease in temperature diminished aggregation of a Fc fusion protein during 
protein A affinity chromatography (Shukla et al. 2007). Additives such as arginine, when 
included in the elution buffer, have shown to enhance recovery of mAbs with a lower 
percentage of aggregates during protein A affinity chromatography; a similar effect has also 
been reported for arginine derivates acetyl-arginine and agmatine (Ejima et al. 2005) . 
 
4.4.5 Filtration 
 
Filtration of protein solutions are carried out to remove particulate material and pathogenic 
microbes (Cromwell et al. 2006). It is also standard laboratory technique to concentrate and 
buffer exchange protein solutions (Liu et al. 2012). 
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Although the process of filtration is intended to remove foreign particles that very often act 
as nuclei for aggregation, particles shed from the filters and membranes of filtration units 
may induce aggregation (Liu et al. 2012). This is a serious matter of concern since protein 
solutions are routinely filtered during various processes in the lifetime of a protein 
therapeutic. Local concentration of proteins is also considered to be higher at the membrane 
surface than in the bulk solution; a condition that might result in aggregation (Cromwell et 
al. 2006). To mitigate such issues, additives such as surfactants are added to prevent 
adsorption to the filter surfaces (Mahler et al. 2010b). The choice of a suitable filter is also 
a necessity; the choice is influenced by the properties of protein of interest.  
 
4.4.6 Shaking, shearing and agitation 
 
Liquid formulations of protein therapeutics are an obvious choice for ease of application; 
however, the solution state of proteins expose them to air-water interfaces and container 
surfaces. The air-water interface is considered to be hydrophobic where proteins potentially 
might accumulate, denature and expose buried hydrophobic regions (Gidalevitz et al. 
1999). This could lead to aggregation during shipping, handling and storage (Treuheit et al. 
2002). Agitation caused by shaking and/or shearing increases the area of such an interface 
further aggregation. For example, recombinant murine growth hormone was observed to 
aggregate on agitation (Fradkin et al. 2011).  
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Addition of surfactants is a common strategy to counter problems caused by air-water 
interfaces (Chi et al. 2003). Surfactants are amphiphilic; they possess both hydrophilic and 
lipophilic properties. They align themselves on water interfaces in a manner that minimizes 
the contact of the hydrophobic regions with water. Two key mechanisms have been 
proposed for surfactant action. In the first mechanism, direct binding of the surfactant to 
protein provides steric hindrance for association of polypeptide chains. Surfactants might 
also bind to folding intermediates and prevent incorrect folding or prevent association of 
the partially unfolded states (Bam et al. 1998, Kreilgaard et al. 1998, Chi et al. 2003). In 
the second mechanism, surfactants compete with proteins for adsorption onto interfaces and 
thereby inhibit proteins from partitioning onto those interfaces.  For instance, propylene 
glycol and polysorbate 20 increased the stability of agitated ciliary neurotrophic factor 
(CNTF) (Arakawa et al. 2003); Tween 20 protected recombinant human growth hormone 
(hGH) from agitation-induced aggregation (Bam et al. 1998). Aggregation of agitated 
polyethylene glycosylated  megakaryocyte growth and development factor (PEG-MGDF), 
polyethylene glycosylated granulocyte colony stimulating factor (PEG-GCSF) and 
osteoprotegerin fused with the Fc portion of an immunoglobulin (OPG-Fc) was also 
inhibited by the addition of polysorbate 20 (Treuheit et al. 2002). However, at certain 
concentrations, polysorbate 20 has shown to increase aggregation of IgG1 antibody (Kiese 
et al. 2008). Furthermore, optimization of container head-space also seems to diminish 
aggregation on agitation (Kiese et al. 2008) and has been observed to prevent the formation 
of visible particles of an IgG A antibody in shaken vials (Brych et al. 2010). 
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4.4.7 Drying 
 
Therapeutic proteins are preferably formulated as aqueous solutions. These liquid 
formulations must be maintained at low temperatures to ensure stability and thus long-term 
storage. However, in some instances, formulation of an aqueous protein solution might not 
be feasible or an attractive option due to reasons such as, lack of proper cold chain during 
shipping and storage. In such situations, proteins are dried to improve their stability 
(Manning et al. 2010). Protein solutions can be dried using methods such as, freeze-drying 
(lyophilization), spray-drying and vacuum drying (Abdul-Fattah et al. 2007, Manning et al. 
2010). 
 
All the methods of drying remove water from protein solution. During this process, the 
protein can be exposed to different stress factors. The water content of a dried protein 
product is often less than 10 % compared to a fully hydrated protein and due to the heavy 
loss in the native hydration layer, the protein structure might undergo sufficient 
perturbation and increased proneness to aggregation (Wang 2005, Hamada et al. 2009). 
Changes in temperature commonly take place during drying processes and cause thermal 
stress on the proteins (Manning et al. 2010). Freeze-drying is known to cause aggregation 
in proteins such as, IgGs and hGH (Sarciaux et al. 1999, Salnikova et al. 2008). Spray-
drying is also known to cause aggregation in IgGs and mAbs (Maury et al. 2005, Andya et 
al. 1999). 
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Excipients are occasionally used to stabilize proteins in the dried state. It is believed that 
the excipients function as ‘water substitutes’; they are thought to mimick the water 
structure by potentially forming hydrogen bonds with the protein. This probably helps 
preserve the secondary structure and inhibit protein unfolding and aggregation (Maury et 
al. 2005, Abdul-Fattah et al. 2007, Salnikova et al. 2008, Manning et al. 2010). 
Compounds commonly utilized to stabilize proteins during drying processes include amino 
acids (arginine and proline), saccharides (sucrose), sorbitol, trehalose and surfactants 
(Andya et al. 1999, Chi et al. 2003, Webb et al. 2003, Maury et al. 2005, Abdul-Fattah et 
al. 2007, Salnikova et al. 2008). Process modifications, such as addition of a heat treatment 
step – annealing – to the lyophilization cycle of a human interferon-γ suppressed 
aggregation (Webb et al. 2003). 
 
4.4.8  Freezing and thawing 
  
Therapeutic proteins are usually stored at low temperatures to inhibit degradation and 
extend the shelf-life. Freezing can be a processing step although exposure to freezing 
temperatures can also occur accidentally, for instance during shipping (Kreilgaard et al. 
1998). This often presents a problem as freezing and thawing are complex processes that 
can induce multiple stresses. Cold denaturation (spontaneous unfolding of protein due to 
cold temperature), increased protein and solute concentrations, changes in pH and ice-
induced denaturation are some of the key reasons for freeze thaw induced aggregation in 
proteins (Bhatnagar et al. 2007, Kueltzo et al. 2008, Manning et al. 2010). For example, 
insoluble aggregates have been observed after freeze-thawing CNTF (Chang et al. 1996). 
Freeze-thawing resulted in the formation of subvisible aggregates of monoclonal IgG1 
ranging from 1 µm to 25 µm along with smaller aggregates (Hawe et al. 2009). 
Aggregation propensity of a model IgG2 increased with freeze-thawing (Kueltzo et al. 
2008). 
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Excipients have been used to control the rate of freezing in an attempt to minimize freezing 
related aggregation (Wang 2005, Cao et al. 2003, Kueltzo et al. 2008, Bee et al. 2011). 
Diverse excipients such as, sugars, polyols, inorganic salts and amino acids are used to 
mitigate aggregation from the freezing process (Carpenter and Crowe 1998, Hamada et al. 
2009). Surfactants are also commonly used (Chang et al. 1996, Kreilgaard et al. 1998, Chi 
et al. 2003). In some cases, excipients might be rendered ineffective at low temperatures. 
Long-term storage at -30° C resulted in the crystallization of sorbitol that adversely affected 
its protective capability and resulted in aggregation of proteins (Piedmonte et al. 2007). 
Similar findings have also been reported for trehalose (Singh et al. 2011).  
 
4.5 Protein aggregates, immunogenicity and regulatory aspects 
 
Protein aggregates are believed to present novel epitopes (multiple-epitope character) that 
is recognized by the immune system as non-endogenous. The non-self molecular epitopes 
presented by the aggregates are commonly encountered in pathogens and thus evoke strong 
immune responses (Hermeling et al. 2004, Cordoba-Rodriguez 2008, Sauerborn et al. 
2010). Of course, not all protein aggregates are immunogenic. Factors that influence the 
immune response include origin of the protein aggregates (endogenous vs. exogenous), 
presence of contaminants and the immunogenic state of the host (Rosenberg 2006). The 
intensity of immune responses is also dependent on the level of tolerance towards the 
aggregates and/or their endogenous counterparts. 
 
The immune system reacts to aggregates by forming antibodies targeted against them. This 
results in a loss of therapeutic efficacy, altered pharmacokinetics that necessitates a new  
dosing regimen or in the neutralization of endogenous proteins (Hermeling et al. 2004, 
Schellekens 2005, Rosenberg 2006, Carpenter et al. 2009). The direst reactions involve 
hypersensitivity and particularly in the case of endogenous proteins serving essential 
biological functions being neutralized, the consequences might be fatal. 
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It is currently not well understood on the nature and sizes of aggregates that are responsible 
for triggering immune responses (Rosenberg 2006, Mahler et al. 2009, Sauerborn et al. 
2010). It is however believed that the immune system recognizes the aggregates more 
readily than the native parent proteins (den Engelsman et al. 2011) and that molecular size 
and solubility of the aggregates are key triggering factors (Rosenberg 2006). The potential 
for inducing immune responses is usually higher for protein aggregates that exceed 100 
kDa in molecular weight; size is not the only determining factor as monomers of a high 
molecular weight protein are not necessarily more immunogenic than their smaller 
counterparts. Thus, the multimeric character of protein aggregates seems to play a 
significant role in recognition and stimulation of the immune response. It also seems that 
insoluble aggregates may be more potent in triggering immune responses. As our current 
understanding of immune responses mediated by protein aggregates is still rather poor, it is 
very important to screen for the presence of protein aggregates and find means to prevent 
the formation of aggregates in protein biopharmaceuticals. However, for patients who are 
immunocompromised, presence of visible aggregates might be of less concern and a lesser 
strict criterion of acceptance applicable (Carpenter et al. 2009, den Engelsman et al. 2011).  
 
Regulatory guidelines exist on acceptable limits and preferred detection methods for visible 
and subvisible particles in injectable biopharmaceuticals for the US and European markets
1
. 
As these regulations are mostly quantitative, no specific regulations for protein aggregates 
in particular exist for the moment (Cordoba-Rodriguez 2008). The regulatory guidelines are 
constantly being updated to incorporate new information and data as they emerge from 
investigations. For example, in its present form, the guidelines do not adequately cover the 
full size-range of protein aggregates. As a consequence, there is a possibility that smaller 
aggregates are routinely ignored. Manufacturers are aware of this fact and on their part 
make efforts to develop and utilize complementary methods to detect and characterize most 
protein aggregates (Cordoba-Rodriguez 2008, Carpenter et al. 2009).  
  
 
                                                 
1
 United States Pharmacopoeia <788>, European Pharmacopoeia 2.9.19 and 2.9.20 
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5 CONCLUSIONS 
 
In this review, we have highlighted the challenges associated with protein aggregation 
towards the development of protein therapeutics. The phenomenon of aggregation is 
complex and currently not well understood. Apart from loss of efficacy, protein aggregates 
are potential risk factors of fatality due to immunogenic responses. The safety concerns 
related to the use of protein products has lead to intense research and setting up of 
regulatory guidelines for detection and characterization of aggregates.  The size and nature 
of protein aggregates in relation to the immunogenic response they elicit is a matter of 
intense research. 
 
Faced with the reality that protein aggregates are unavoidable, their presence and nature 
needs to be detected and characterized. No single analytical tool offers aggregate detection 
of all size ranges and every method has its set of limitations. Generally, it is appreciated 
that different methods are used orthogonally and results from one is compared and 
validated against another. Some methods are more applicable for rapid detection whereas 
others more suited for detailed characterization.  
 
The field of research on protein aggregation is evolving and new methods are being 
developed to effectively characterize aggregation.  Such efforts will not only help in 
addressing safety concerns but also in understanding mechanisms of aggregate formation 
and formulation of inhibition strategies.  
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1 INTRODUCTION 
 
Neurotrophic factors are proteins that have a multitude of functions within the nervous 
system. They regulate survival, proliferation, differentiation of neurons and other cell types 
in the nervous system, such as dendrocytes and glial cells (Chao 2003, Wen et al. 2012). 
Ciliary neurotrophic factor (CNTF) was initially identified in chick embryo extract (Adler 
et al. 1979, Varon et al. 1979). Human CNTF (hCNTF), a 23 kDa polypeptide, has 200 
amino acid residues (Richardson 1994, Wen et al. 2012). It belongs to the interleukin-6 (IL-
6) family of neuropoietic cytokines (McDonald et al. 1995, Wen et al. 2012). It is a 
cytosolic protein under normal physiological conditions and is released upon damage to the 
cells expressing CNTF, such as glial cells and astrocytes (Sleeman et al. 2000, Cognet et al. 
2004, Wen et al. 2012). 
 
CNTF exerts its biological function on different types of cells in the nervous system, e.g., 
photoreceptors and skeletal muscle (Wen et al. 2006). CNTF promotes the survival of 
neurons (Dutta et al. 2007), photoreceptors and is known to have a protective influence on 
the outer segments of the cone receptor cells (Li et al. 2010).  CNTF is also known to 
influence the energy balance (Ott et al. 2002, Wen et al. 2012). The therapeutic potential of 
CNTF therefore ranges from neurodegenerative diseases (amyotrophic lateral sclerosis 
[ALS], Huntington’s disease [HD], age-related macular degeneration [AMD]) to metabolic 
disorders such as, obesity and type II diabetes (Sleeman et al. 2000, Ettinger et al. 2003, 
Cognet et al. 2004). Successful clinical studies with hCNTF-secreting implants for the 
treatment of retinitis pigmentosa and dry AMD have been conducted (Sieving et al. 2006, 
Wen et al. 2012). 
 
The tertiary structure of CNTF consists of a bundle of four anti-parallel α-helices (A 
[Arg13-His41], B [Glu69-Val96], C[Phe105-Leu129] and D [Phe152-Ser180]) with cross-
over loops between helices A-B and C-D and a single short loop between helices B-C 
(Figure 1a). (McDonald et al. 1995, Kallen et al. 1999). hCNTF lacks a signal peptide and 
a consensus sequence for glycosylation. 
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(a) 
 
(b) 
 
Figure 1: (a) Crystal structure of hCNTF (2-187) dimer. Helices A, B, C and D are 
depicted with yellow, cyan, red and blue, respectively; (b) Residues attributed to binding to 
CNTFRα. 
 
CNTF mediates its activity by binding to a tripartite receptor complex consisting of CNTF 
receptor subunit alpha (CNTFRα) (Davis et al. 1991) and the trans-membrane signal 
transducing subunits gp130 and Leukemia inhibitory factor (LIF) receptor β (LIFRβ) 
(Davis et al. 1993b). The CNTFRα-binding surface epitope of CNTF was studied with 
random mutagenesis and identified to consist of residues Arg25, Arg28, Gln63, Trp64, 
Gln74, Asp175 and Arg177
 
(Panayotatos et al. 1995). These residues are located in helix A, 
the loop between helices A-B, helix B and helix D, are spatially clustered and surface 
accessible (Figure 1b). CNTFRα is a peripheral membrane protein linked to the cell 
membrane with a glycosyl-phosphatidylinositol-linkage (Davis et al. 1991) and is also 
known to exist as a soluble receptor (sCNTFRα) after phospholipase C mediated cleavage 
(Davis et al. 1993a). In humans, binding of CNTF to CNTFRα results in the recruitment of 
gp130 and LIFRβ that eventually activates signal transduction.  
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hCNTF is also known to bind with lower affinity to both, membrane-bound and soluble 
human IL-6 receptor α chain (IL-6Rα), a structural relative of CNTFRα (Davis et al. 1991, 
Davis et al. 1993b. This is possibly an alternate arrangement to form receptor complex to 
activate downstream signal transduction processes (Schuster et al. 2003). These 
observations offer an explanation as to why cells expressing gp130 and LIFRβ but not 
CNTFRα (e.g. human liver cells) are still responsive to CNTF (Sleeman et al. 2000, 
Schuster et al. 2003, Cognet et al. 2004). The side effects caused by higher doses of CNTF 
have also been partially attributed to the formation of IL-6Rα/gp130/LIFRβ receptor 
complex (Schuster et al. 2003, Wagener et al. 2014). 
 
Clinical and investigative biological studies are often limited by the amount of pure protein 
available (Peti & Page 2007). Isolation and purification of protein from natural sources 
such as tissues, is often cumbersome, limited in amounts and poses challenges in 
purification.  This necessitates heterologous recombinant expression of the protein of 
interest. The recombinant technology to express proteins has been successfully utilized to 
produce many therapeutic proteins.  Some examples from the recent-past include human 
insulin (Goeddel et al. 1979), human growth hormone (Olson et al. 1981), erythropoietin 
(Winearls 1998) and antibodies (Better et al. 1988, Skerra and Plückthun 1988). Currently, 
therapeutic proteins are routinely expressed in mammalian cells, in yeasts, and in bacterial 
cells, such as Escherichia coli (Gengross 2004, Nayak 2010, Walsh 2010, Bandranayake 
and Almo 2014). Recent advances in the production of protein therapeutics include 
producing therapeutic proteins in plants and transgenic animals (Nayak 2010, Walsh 2010). 
Notable accomplishments include approvals for the first proteins expressed in baculovirus-
infected insect cells and in the yeast Pichia pastoris (Walsh 2010); taliglucerase alpha was 
the first recombinant protein produced in plant cells (procuded in cultured carrot cells) to 
receive US Food and Drug Administration (FDA) approval (Aggarwal 2012), while 
Ecallantide and the proteins in the human papilloma virus (HPV) vaccine Cervarix were the 
first approved therapeutic proteins produced in baculovirus-infected insect cells and in the 
yeast Pichia pastoris, respectively (Walsh 2010). 
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Different recombinant expression systems exist for protein production and the choice for a 
particular system is governed by the characteristics of the protein of interest. Eukaryotic 
expression systems (Jarvis 2003, Gräslund et al. 2008, Yin et al. 2007, Tworak et al. 2011) 
include yeast (Pichia pastoris, Saccharomyces cerevisiae), baculovirus-infected insect cells 
(Sf9, Tn-5B1-4) and mammalian cells (CHO, HEK). The yeast system offers operational 
simplicity and is inexpensive. It is capable of forming disulphide bonds and carrying out 
post-translational modifications (PTMs) such as glycosylation. The extent of glycosylation 
is usually different from that achieved in mammalian systems and this might limits its 
applicability. Baculovirus-infected insect cells are able to carry out PTMs similar to higher 
eukaryotic systems; however, their transient transfection renders them unsuitable for 
continuous fermentation. Mammalian cells produce proteins with correct PTMs and 
structural fold.  The system is however complex, time consuming and costly. Among the 
prokaryotes, the enterobacterium Escherichia coli is the most versatile and economical 
expression system. They are commonly referred to as the ‘laboratory workhorses’ for their 
utility in protein production (Baneyx and Mujacic 2004). However, recombinant expression 
of eukaryotic proteins (especially of human origin) in E. coli is a challenging issue (Sahdev 
et al. 2008). Inefficient or improper folding of recombinant proteins due to lack of 
eukaryotic transcriptional machinery in E. coli (e.g., disulphide bond formation and 
glycosylation) might result in the expression of non-native, non-functional protein. 
Improper folding often results in the formation of insoluble aggregates known as inclusion 
bodies (Baneyx and Mujacic 2004, Sørensen & Mortensen 2005). E. coli’s inability to 
effect PTMs limits its utility as a robust expression system for eukaryotic proteins (Baneyx 
and Mujacic 2004, Sahdev et al. 2008).  
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Earlier efforts to produce recombinant hCNTF in E. coli have been limited by low yields 
and the need to refold the protein from inclusion bodies (McDonald et al. 1991, 
Masiakowski et al. 1991, Negro et al. 1991, McDonald et al. 1995, Wagener et al. 2014). 
For therapeutic protein production, refolding from inclusion bodies is not desirable; it not 
only complicates the manufacturing process but also the possibility of protein aggregation 
raises the risk of immunogenic reactions. An effective, economical expression system for 
soluble production of hCNTF is highly desirable towards its development as a therapeutic 
agent.  
 
 
2 AIM 
 
The objective of our work was to express soluble and functional hCNTF in Escherichia 
coli. Towards the realization of our goal, the following experiments were carried out: 
 
 Codon optimization of the hCNTF sequence for expression in E. coli 
 
 Expression plasmids with nine different fusion partners and codon optimized 
hCNTF were constructed for enhanced solubility/facilitated folding of the expressed 
‘fusion tag – hCNTF’ construct 
 
 Small-scale expression screening for soluble expression of hCNTF. 
 
 Large-scale expression, purification of hCNTF. 
 
 In vitro binding of hCNTF to hCNTFRα 
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3  MATERIALS AND METHODS 
 
3.1 Codon optimization 
 
The codons of the hCNTF gene were optimized based on codon preference usage in E. coli 
using a commercial proprietary algorithm, OptimumGene
TM
 (GenScript, NJ, USA). Variety 
of parameters were optimized, including codon usage bias, GC content, CpG dinucleotides 
content, mRNA secondary structure, cryptic splicing sites, premature PolyA sites, internal 
chi sites and ribosomal binding sites, negative CpG islands, RNA instability motif, repeat 
sequences. The synthetic gene was purchased from GenScript, US. 
 
3.2 Construction of expression vectors 
 
Preparation of E. coli competent cells, bacterial transformation, plasmid DNA purification 
and plasmid DNA digestion are prescribed in APPENDICES 1, 2, 3 and 4, respectively. 
 
3.2.1 Polymerase chain reaction (PCR) amplification of hCNTF construct 
 
Primers for amplifying the hCNTF sequence were designed using the NetPrimer software 
(PREMIER Biosoft). The forward and reverse primers were designed to contain overhang 
sequences AAGTTCTGTTTCAGGGCCCG and ATGGTCTAGAAAGCTTTA, 
respectively (Bird 2011). The primers were procured from Eurofins MWG Operon; Table 1 
lists the full sequence of the primers. 
 
Table 1: Primers used for amplification of hCNTF.  
Primer Sequence (5' → 3') Tm (°C) 
CNTF_1_fp AAGTTCTGTTTCAGGGCCCGATGGCGTTTACCGAACATTCC 60 
CNTF_200_rp ATGGTCTAGAAAGCTTTACATCTTCTTGTTGTTTGCGATGTAG 60 
Sequences in blue and red denote overhangs, sequences in green denote complementary sequences of hCNTF; 
fp and rp denotes forward and reverse primers, respectively. 
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PCR amplification was carried out using KOD Hot Start DNA Polymerase (Novagen). The 
reactions were set-up on ice as in Table 2. 
 
Table 2: PCR reaction set-up. 
Component Final concentration in 50 µl 
KOD Hot Start Buffer 1 x 
dNTP mix 0.2 mM 
MgSO4  1.5 mM 
Forward primer 0.3 µM 
Reverse primer 0.3 µM 
Template DNA 0.2 ng/µl 
KOD Hot Start DNA Polymerase 0.02 U/µl 
                                                                                 
The thermal cycling carried out is depicted in Figure 2. The reaction mixture was analyzed 
by gel electrophoresis (0.7 % agarose, Bionordika; TAE buffer). The gel contained 0.5 
mg/ml of ethidium bromide and the run was carried out at 110 V for 50 minutes. Samples 
were prepared with 5 µl of each PCR reaction mixture and 6X sample buffer. 5µl of each 
sample was loaded to the gel. 
 
 
Figure 2: PCR thermal cycle 
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3.2.2 Cloning of hCNTF into pOPIN vectors 
 
The suite of nine pOPIN vectors (Oxford Protein Production Facility, UK [OPPF-UK]) 
used for cloning hCNTF gene is listed in Table 3. All nine fusion partners contained an N-
terminal His6-affinity tag to facilitate the subsequent purification of the fusion protein, and 
a Rhinovirus 3C protease cleavage site between the N-terminal fusion partner and the target 
protein to facilitate the removal of said fusion partner.  All the vectors contained common 
restriction sites, HindIII and KpnI; this facilitated parallel cloning. 
 
Linearized plasmid vectors and PCR-amplified hCNTF insert was purified by gel 
extraction. Details of gel extraction protocol are provided in APPENDIX 5. hCNTF gene 
was inserted into linearized pOPIN vectors using the Gibson Assembly
TM
 Cloning Kit 
(NEB).  
 
20 µl of the cloning reaction mixture  consisted of 75 - 100 ng of the linearized vector, 
inserts in a 2-fold molar excess of the vector, 10 µl of 2 X Gibson Assembly Master Mix,. 
The reactions were incubated at 50°C for 25 minutes. After incubation, the reaction 
mixtures were placed on ice (to arrest the reaction) and subsequently 2 µl was used to 
transform NEB 5-alpha (New England BioLabs) E. coli competent cells. Details of the 
transformation protocol are provided in APPENDIX 2.  
 
The transformed cells were plated on LB-agar plates supplemented with ampicillin
1
, 80 
µg/ml X-gal and 0.3 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG). The plates were 
incubated overnight at 37°C. Separate colonies were used to inoculate 5 ml liquid cultures 
for DNA plasmid preparation (detailed in APPENDIX 3). 
 
                                                 
1
 Throughout the course of this work, antibiotic concentrations used in cultures were 100 µg/ml and 34 µg/ml 
for ampicillin (ICN) and chloramphenicol (ICN), respectively. 
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3.2.3 Validation of positive clones 
 
Validation of the cloned constructs were carried out by PCR amplifying the full-length 
fusion construct (fusion tag – hCNTF) using Pfu DNA Polymerase (Thermo Scientific). 
The forward primers used were specific to each fusion tag in the vector and the reverse 
primer was specific to the C-terminus of hCNTF. The primers used for validation are listed 
in Table 3. PCR reaction set up and thermal cycle is depicted in Table 4 and Figure 3, 
respectively. 
 
Table 3: Primers for PCR amplification of the constructs. fp denotes forward primer, 
while rp denotes reverse primer. 
Primer Sequence (5' → 3') Tm (°C) 
pOPINF_2357_fp AGCAGCGGTCTGGAAGTTCTGTTT 65 
pOPINS3C_2357_fp GGGAGCGATAGCGAAGTGAACCA 67 
pOPINTRX_2357_fp AGCGATAAAATTATTCACCTGACTGACGAC 68 
pOPINMSYB_2357_fp ACCATGTACGCAACGCTTGAAGAAG 66 
pOPINJ_2357_fp ATGTCCCCTATACTAGGTTATTGGAAAATTAAG 65 
pOPINHALO7_2333_fp ATGGCACACCATCACCACCATCAC 67 
pOPINM_2357_fp AGCAGCGGCATGAAAATCGAAG 65 
pOPINTF_2357_fp CAAGTTTCAGTTGAAACCACTCAAGGC 66 
pOPINNusA_2333_fp ATGGCACACCATCACCACCATCAC 67 
CNTF_200_rp CATCTTCTTGTTGTTTGCGATGTAGTGC 67 
 
Table 4: PCR reaction set-up 
 Component Final concentration in 50 µl 
Pfu Buffer with MgSO4 1 x 
dNTP mix 0.2 mM 
Forward primer 0.3 µM 
Reverse primer 0.3 µM 
Template DNA 0.2 ng/µl 
Pfu DNA Polymerase 0.02 U/µl 
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Figure 3. PCR thermal cycle for the PCR-check 
 
After PCR-amplification, 5 µl of each reaction mixture was loaded to an agarose gel (0.7 % 
agarose, TAE buffer). The electrophoresis run was carried out at 110 V for 70 minutes. The 
size of the constructs as obtained from PCR validation is listed in Table 5. 
 
Table 5: Sizes of tag sequences coupled with hCNTF sequence 
Vector 
Size of ‘fusion tag – 
hCNTF’ constructs 
(bp) 
pOPINF 668 
pOPINS3C 956 
pOPINTRX 992 
pOPINMSYB 1037 
pOPINJ 1331 
pOPINHALO7 1550 
pOPINM 1778 
pOPINTF 1961 
pOPINNusA 2150 
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3.3 Protein expression screening 
 
3.3.1 Small scale expression 
 
Expression strains BL21(DE3)pLyS (Novagen) and Rosetta 2(DE3)pLysS (Novagen) – a 
derivative of BL21 engineered to supply tRNAs for 7 rare codons; AGA, AGG, AUA, 
CUA, GGA, CCC and CGG – were transformed with the plasmids. Single colonies were 
used to inoculate 0.7 ml of (Power Prime Broth [PPB] [AthenaEs]) (supplemented with 
ampicillin and chloramphenicol) on a multiwall plate and grown overnight at 37°C with 
shaking at 250 rpm. 
 
150 µl and 250 µl of seed cultures from BL21(DE3)pLysS, and Rosetta 2(DE3)pLysS, 
respectively were used to inoculate 3 ml of expression culture (PPB / Overnight Express™ 
Instant TB Media [TBONEX] [Novagen] supplemented with ampicillin and 
chloramphenicol) on a multiwall plate. The cultures were grown at 37°C with shaking at 
250 rpm to a OD600 value of 0.5. 
 
For protein expression at 37°C in PPB, induction was carried out with 1mM IPTG and 
grown for 4 h with shaking at 250 rpm. For expression at 20°C with PPB, the cultures were 
cooled on the bench-top for 15 minutes before adding 1mM IPTG. The culture was grown 
at 20°C for 18 h with shaking at 250 rpm. Expression in TBONEX media was carried out at 
25°C for 24 h with shaking at 225 rpm. 
 
The cells were harvested by centrifugation (3650 rpm) for 35 minutes at 4°C. The 
supernatants were discarded and pellets washed with 210 µl of NPI-10 (50 mM NaH2PO4, 
300 mM NaCl, pH 8.0; 10 mM Imidazole) and centrifuged (3650 rpm) for 35 minutes at 
4°C. The wash liquid was discarded and the cell pellets were stored at -80°C. 
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3.3.2 Estimation of soluble fraction 
 
Cell pellets were thawed at room temperature. The pellets were resuspended in 250 µl of 
buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0; 0.2 % Tween 20) and the suspended cells 
were transferred to microcentrifuge tubes. The samples were freeze-thawed three times 
(liquid nitrogen and 37°C water bath). 50 µl of cell mixtures were transferred to  
microcentrifuge tubes followed by 1 µl of Lysonase™ Bioprocessing Reagent (EMD 
Millipore). The cell mixtures were incubated at room temperature with shaking at 270 rpm 
for 45 minutes. 
 
After incubation, the homogenized samples were divided into two equal fractions of 25 µl 
each. For the fraction ‘total protein’; 25 µl of water and 10 µl of 6x SDS-PAGE sample 
buffer was added and the mixture heated at 95°C for 15 minutes. The mixture was then 
centrifuged at 21,100 g for 15 minutes. The supernatants were transferred to 
microcentrifuge tubes and stored at -20°C. For the fraction, ‘soluble protein’; 25 µl cell 
suspensions were centrifuged at 21,100 g for 15 minutes and the supernatants transferred to 
microcentrifuge tubes. 25 µl of water and 10 µl of 6X SDS-PAGE sample buffer were 
added to the supernatants and the samples were heated at 95°C for 15 minutes. The samples 
were stored at -20°C and further analyzed by SDS-PAGE gel electrophoresis.  
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3.3.3 Affinity purification of soluble fraction 
 
Frozen cell pellets were thawed on 42°C water bath for 15 minutes followed by 210 µl of 
resuspension buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0; 10 mM Imidazole, 1 mM 
DL-dithiothreitol [DTT, Sigma], Protease Inhibitor Cocktail [PIC, Sigma]
2
) was added to 
the cell suspension. The freeze thaw cycle was repeated three times with mixing in between 
cycles. After freeze-thawing, 1 µl of Lysonase was added to the pellet suspensions and 
incubated with shaking (270 rpm) at room temperature for 45 minutes. After incubation, the 
lysates were transferred to microcentrifuge tubes and centrifugation (21,100 g) was carried 
out at 4°C for 40 minutes. 
 
20 µl of fully suspended nickel nitriloacetic (Ni-NTA) magnetic beads (Genscript, NJ, 
USA) was dispensed to the wells of a flat bottom plate. 200 µl of NPI-10-Tween buffer (50 
mM NaH2PO4, 300 mM NaCl, pH 8.0; 10 mM Imidazole, 1% Tween 20) was added to 
each well and the plate was gently agitated (270 rpm) at room temperature for 7 minutes. 
The plate was then placed on a 96-well Magnetic Separation Rack (New England Biolabs) 
for 5 minutes following which the buffer was removed by aspiration. The washing of the 
beads was repeated 3 times. 
 
Supernatants from cell lysates were transferred to the wells containing the magnetic beads 
and incubated with shaking (270 rpm) at room temperature for 55 minutes. The plate was 
then placed on the magnetic rack for 5 minutes and the supernatant discarded. The beads 
were washed 4X with NPI-20-Tween buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0; 20 
mM Imidazole, 0.05% Tween 20, 1 mM DTT) to remove unbound proteins. 
 
                                                 
2
 Throughout the course of this work, whenever buffers were supplemented with PIC, this was done in a 
1:100 dilution 
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The bound proteins were eluted by adding 50 µl of NPI-250-Tween buffer (50 mM 
NaH2PO4, 300 mM NaCl, pH 8.0; 250 mM Imidazole, 0.05% Tween 20, 1 mM DTT). The 
plate was shaken (270 rpm) at room temperature for 10 minutes followed by placing it  on 
the magnetic rack for 7 minutes. 45 µl of supernatants were transferred to microcentrifuge 
tubes. 9 µl of 6X SDS-PAGE sample buffer was added to each tube and heated at 95°C for 
7 minutes and stored at -20°C for further analysis with SDS-PAGE gel electrophoresis. 
 
3.3.4 Analysis with SDS-PAGE 
 
Percentage of soluble protein fraction was estimated by using GelQuant.NET software (V 
1.7.8) from biochemlabsolutions.com. Band intensities of soluble and total protein fractions 
in the gel were measured three times and averaged. Procedural details of SDS-PAGE gel 
electrophoresis are outlined in APPENDIX 6. 
 
3.4 Large scale protein expression and purification 
 
6His-hCNTF construct was used for large-scale protein expression and purification. 
Transformed single separate Rosetta 2 (DE3) pLysS colonies were used to inoculate 20 ml 
of LB media supplemented with ampicillin and chloramphenicol. The cultures were grown 
at 25°C for 15 hours with shaking at 225 rpm. 450 ml of TBONEX was inoculated with 
overnight culture (in a ratio of 30:1) and the culture grown at 25°C with shaking (225 rpm) 
for 24 hours. The cells were harvested by centrifugation (10,000 g) at 4°C for 30 minutes 
and the supernatant removed. The pellets were washed and re-suspended in 20 ml of NPI-
10 (50 mM NaH2PO4, 300 mM NaCl, pH 8.0; 10 mM Imidazole) followed by 
centrifugation (10,000 g) at 4°C for 30 minutes. The supernatant was removed, the pellets 
weighed and stored at -80°C. 
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The frozen cell pellet was thawed and re-suspended in lysis buffer
3
. The cell suspension 
was freeze-thawed 3X (alternating between -80°C and 37°C). After the freeze thaw cycle, 
Lysonase was added to the mixture and incubated at room temperature for 90 minutes with 
gentle agitation. The lysate was then centrifuged (14,500 g) at 4°C for 50 minutes and the 
supernatant reserved for purification. 
 
7.0 g of Ni-IDA was suspended in 8 bed volumes of NP-buffer (50 mM NaH2PO4, 300 mM 
NaCl, pH 8.0; 5 % glycerol, 0.2 % Tween 20 supplemented with 1mM DTT and PIC). The 
suspension was rocked gently at room temperature for 15 minutes followed by 
centrifugation at 500 g for 3 minutes. The supernatant was removed and this process was 
repeated one more time. The resin was finally re-suspended in 8 bed volumes of NP-buffer. 
 
Supernatant from cell lysate was added to Ni-IDA resin and incubated at 4°C for 120 
minutes with gentle agitation. Centrifugation was then carried out at 500 g for 3 minutes 
and the supernatant removed.  
Unbound proteins were removed by washing (gently agitated for 10 minutes followed by  
centrifugation at 500 g for 3 minutes) the resin with 4 bed volumes of NPI-10-Tween (50 
mM NaH2PO4, 300 mM NaCl, pH 8.0; 10 mM Imidazole, 5 % glycerol, 0.2% Tween 20 
supplemented with 1mM DTT and PIC). Further washings were carried out 1X with NPI-
20-Tween (50 mM NaH2PO4, 300 mM NaCl, pH 8.0; 20 mM Imidazole, 5 % glycerol, 
0.2% Tween 20 supplemented with 1 mM DTT and PIC) and NPI-40-Tween (50 mM 
NaH2PO4, 300 mM NaCl, pH 8.0; 40 mM Imidazole 5 % glycerol, 0.2 % Tween 20, 
supplemented with 1 mM DTT and PIC). 
 
                                                 
3
 Estimation of resin amount for optimal IMAC purification is described in APPENDIX 10 
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Bound protein(s) was eluted in a stepwise manner (1X with 1 bed volume, 2X with 2 bed 
volumes and 3X with 1.33 bed volumes; incubation at room temperature for 15 minutes 
with gentle agitation followed by centrifugation at 500 g for 3 minutes) with elution buffer 
(50 mM NaH2PO4, 300 mM NaCl, pH 8.0; 250mM Imidazole, 5% glycerol, 0.2% Tween 
20 supplemented with 1 mM DTT and PIC). 7 µl of each elution fraction was used for 
SDS-PAGE gel electrophoresis analysis. Relevant elution fractions were pooled, buffer 
exchanged (100 mM NaH2PO4, 300 mM NaCl, pH 8.0) and concentrated to 6 ml using 
Amicon® Ultra-4 Centrifugal filter units (Merck Millipore) with a 3 kDa molecular weight 
cut off. 
 
Concentrated protein sample after Ni-IDA purification was applied to HiLoad Superdex 
200 prep grade gel filtration column (2.6 x 60 cm) equilibrated with buffer containing 100 
mM NaH2PO4, 300 mM NaCl, pH 8.0; 1 mM DTT. Relevant protein fractions were pooled, 
concentrated and buffer exchanged in 100 mM NaH2PO4, 50 mM NaCl pH 8.0; 2 mM DTT 
using Amicon® Ultra-4 centrifugal filter units. 
 
3.5 In vitro activity assay of hCNTF 
 
3.5.1 Fluorescent labeling of hCNTF 
 
hCNTF was labeled with biotin using EZ-Link™ NHS-PEG4-Biotinylation Kit (Thermo 
Scientific). The biotinylation reaction was carried out in a carbonate buffered solution (100 
mM  NaHCO3, 100 mM  Na2CO3) in dimethylformamide (DMF) in 20:1 molar ratio of 
NHS-PEG4 Biotin to hCNTF at room temperature for 2 h with gentle agitation. Buffer 
exchange was carried out in 100 mM NaH2PO4, 50 mM NaCl, pH 8.0 to remove excess 
NHS-PEG4 Biotin. 
 
17 
 
3.5.2 Binding of biotinylated hCNTF to hCNTFR  
 
Nunc MaxiSorp® flat-bottom 96-well plate was washed 2X with BupH™ Phosphate 
Buffered Saline (PBS, ThermoScientific). 1 µg of human CNTFRα (hCNTFRα; Sino 
Biological Inc.) in PBS was added to the wells of the plate and incubated overnight at +4°C 
with gentle shaking. The wells were washed 3X with 50 mM Tris-HCl, 150 mM NaCl, 
0.05% Tween 20 (TBS-T); pH 7.0. To reduce unspecific binding to the plate surface, 
blocking was carried out by adding 300 µl of 2% bovine serum albumin (BSA) in TBS-T to 
each well followed by incubation at room temperature for 90 minutes with gentle agitation. 
The wells were then washed 4X with TBS-T. 
 
0.2, 0.5, 1.0, 1.5, 2.0 and 3.0 µg of biotinylated hCNTF (bCNTF) (contained in 100 µl of 
0.1 % BSA in TBS-T) were added to the wells containing hCNTFRα. To account for 
unspecific binding, 3 µg of unlabeled hCNTF (contained in 100 µl of 0.1 % BSA in TBS-
T) was added to the wells. The plate was incubated for 2 h at room temperature with gentle 
shaking followed by washing 4X with TBS-T. 50 ng of HRP (horseradish peroxidase) –
conjugated streptavidin (Thermo Scientific) in 100 µl of 0.5% BSA in TBS-T was added to 
the wells and incubated at room temperature for 70 minutes with gentle agitation. This was 
followed by 4X washings with TBS-T. 
 
200 µl of TMB (3,3’,5,5’-tetramethylbenzidine) substrate solution (Thermo Scientific) was 
added to the wells and incubated at room temperature with shaking for 20 minutes. The 
reaction was stopped with 2 M H2SO4. After gentle mixing, optical density of the well 
solutions was measured at 450 nm using a spectrophotometer (Varioskan Flash, Thermo 
Scientific, Waltham, MA, USA). 
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4 RESULTS AND DISCUSSION 
 
Previous studies of hCNTF expression in E. coli (BL21) have reported low soluble amounts 
and the need to purify from inclusion bodies (McDonald et al. 1991, Masiakowski et al. 
1991, Negro et al. 1991, McDonald et al. 1995, Wagener et al. 2014). In one study, only 
13% of soluble hCNTF was obtained from cell extracts. Other studies have reported the 
presence of hCNTF in amounts as high as 80 % in the insoluble fraction (Negro et al. 1991) 
although in one report, translation of hCNTF was 20 – 40% of the total protein 
(Masiakowski et al. 1991). Challenges of recombinant expression of eukaryotic proteins in 
bacterial hosts such as E. coli, stem from the fact that they are often limited in amounts of 
tRNA for codons that are used less frequently. This might result in non-optimal translation, 
termination, frame shifting and low levels of protein expression (Kane 1995, Calderone et 
al. 1996). Non-optimal structural features of mRNA are also believed to adversely affect 
protein expression (Kudla et al. 2009, Welch et al. 2009). To mitigate issues arising from 
codon preference usage, cell strains engineered to supply tRNAs for codons rarely found in 
E. coli have been used or the gene of interest has been codon optimized for preferential use 
in E. coli (Peti & Page 2007, Burgess-Brown et al. 2008, Sahdev et al. 2008).  Codon 
optimization enhanced expression of pigment epithelium-derived factor (Gvritishvili et al. 
2010) and thirty human short chain dehydrogenase/reductase genes showed improved 
expression with optimized codon and use of E. coli strains containing rare codon tRNAs 
(Burgess-Brown et al. 2008). 
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The other limiting factor with heterologous expression in E. coli arises from improper 
folding of the polypeptide chain and subsequent formation of insoluble aggregates, 
commonly referred to as inclusion bodies. Refolding of proteins from inclusion bodies 
often requires extensive optimization and might often result in non-native conformational 
states with propensity to aggregate; this is not desirable for therapeutic protein production. 
Co-expression of molecular chaperones (proteins that assist folding) along with the target 
protein of interest and using cell strains that have been engineered to aid protein folding via 
the formation of disulfide bonds have proved beneficial towards soluble expression of 
natively folded proteins (Baneyx and Mujacic 2004, Sørensen & Mortensen 2005, Sahdev 
et al. 2008). 
 
Soluble protein expression in E. coli has also been facilitated by the fusion of soluble ‘tags’ 
(protein / peptide fragments) at the N-terminus of the protein of interest. The fusion tags 
can be cleaved off with a site-specific protease after successful expression of soluble fusion 
construct. Fusion ‘tags’ are known to improve expression yield, reduce susceptibility to 
proteolysis and might also serve as affinity ‘tags’ to facilitate purification of the expressed 
proteins (Waugh 2005, Arnau et al. 2006, Esposito & Chatterjee 2006, Peti & Page 2007, 
Sahdev et al. 2008, Huang et al. 2012). However, no general rules apply to the choice of a 
particular fusion ‘tag’ for a protein of interest and the process of trial-and-error is usually 
followed. Comparisons of the utility of various fusion tags with different proteins have 
been reported (Hammarström et al. 2002, Bird 2011, Huang et al. 2012). Other factors such 
as, decreased temperature of growth is also known to be helpful for soluble expression of 
proteins (Vasina and Baneyx 1997). 
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Successful protein expression in E. coli remains largely a trial-and-error process. Small-
scale expression screens have emerged as an effective approach to test and identify various 
conditions (culture media, temperature, expression strains, fusion tags) in parallel for 
optimal protein expression (Berrow et al. 2006, Gräslund et al. 2008). In our efforts to 
express soluble hCNTF, we combined the twin strategies of codon optimization and using a 
set of nine different soluble tags to set up a factorial screen covering conditions of 
temperature, growth media and bacterial strains. The overall strategy is depicted in Scheme 
1. 
 
 
Scheme 1: Depiction of the strategy of parallel cloning, small scale expression screening 
and large scale expression of hCNTF 
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4.1 Construction of expression vectors 
 
Full-length hCNTF gene was successfully amplified by PCR (Figure 4) and purified by gel 
extraction.  Details of gel extraction and purification have been provided in APPENDIX 5. 
 
 
 
Figure 4. PCR-amplified hCNTF. M denotes DNA marker (bp); lanes 1 and 2 denote 
amplified hCNTF from reaction conditions without and with 3 % DMSO, respectively. 
 
4.2 Cloning of hCNTF into pOPIN vectors
 
 
Purified hCNTF gene was cloned into nine different pOPIN vectors (Scheme 2 and Table 
6) and three positive clones were picked based on blue / white screening (Matthews 2005). 
Plasmids were isolated from each of the three clones for all the nine fusion constructs and 
validated for the presence of the insert (fusion construct) by PCR. A cloning efficiency of 
100% was achieved (Figure 5). 
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Scheme 2: Scheme depicting the cloning strategy
4
 
 
Table 6: Sizes of expression vectors 
Vector Fusion partner 
Tag-hCNTF 
insert size (bp) 
pOPINF MAHis6 -SSGLEVLQF↓GP tag 5531 
pOPINS3C Small ubiquitin-modifier 5824 
pOPINTRX Thioredoxin 5860 
pOPINMSYB MsyB tag 5905 
pOPINJ Glutathione-S-Transferase 6218 
pOPINHALO7 HaloTag 6413 
pOPINM Maltose binding protein 6665 
pOPINTF Trigger Factor 6824 
pOPINNusA N-utilisation substance A 7013 
 
                                                 
4
 The discrepancy caused by a single nucleotide mismatch is a remnant from when the expression vectors 
were engineered. As it doesn’t interfere with the cloning process, it has been left in the sequence. 
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Figure 5. PCR validation of Tag-hCNTF constructs. M denotes marker; lane groupings 
1 - 9 denote hCNTF fusion constructs cloned into vectors pOPINF, pOPINS3C, 
pOPINTRX, pOPINMSYB, pOPINJ, pOPINHALO7, pOPINM, pOPINTF and 
pOPINNusA, respectively. A, B and C denote the three colonies screened for each 
construct. 
 
4.3 Small-scale protein expression screen 
 
4.3.1 Estimation of percentage soluble fraction 
 
All-in-all 54 different combinations of expression conditions were assessed. Most 
conditions (constructs/temperature/media/strains) screened showed the presence of soluble 
hCNTF constructs. The percentage of hCNTF in the soluble fraction (relative to the total 
protein) was over 80 – 90 % in most of the expression conditions tested (Figure 6). Our 
results highlight the huge improvement achieved in soluble expression of hCNTF in E. coli 
as compared to previous reports of less than 20 % (Masiakowski et al. 1991, McDonald et 
al. 1991, Negro et al. 1991, Wagener et al. 2014). 
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(a) 
 
(b) 
 
(c) 
 
(d) 
 
(e) 
 
(f) 
 
Figure 6. Histograms showing percentage soluble fraction of hCNTF in expression 
screen
5
. (a) BL21/20°C/ PPB; (b) BL21/25°C/ TBONEX; (c) BL21/37°C/ PPB; (d) Rosetta 
2/20°C/ PPB; (e) Rosetta 2/25°C/ TBONEX; (f) Rosetta 2/37°C/ PPB. 
 
4.3.2 Affinity purification of soluble protein 
 
Table 7: Expression vectors and their fusion tags. 
   BL21 Rosetta 2 
Lane Vector Fusion tag 
20° C 25° C 37° C 20° C 25° C 37° C 
PPB TBONEX PPB PPB TBONEX PPB 
1 pOPINF 6-His- 1 1 1 1 1 1 
2 pOPINS3C 6-His-SUMO- 0.7 1.5 2.1 1.3 2.7 1.1 
3 pOPINTRX 6-His-Thioredoxin 1.2 1.7 4.9 1.1 0.7 0.1 
4 pOPINMSYB 6-His-MsyB- 0.5 0.8 2.9 1.8 3.6 2.0 
5 pOPINJ 6-His-GST- 0.3 1.3 0.4 0.1 0.5 0.1 
6 pOPINHALO7 6-His-Halo- 1.5 1.6 1.7 1.6 3.0 2.0 
7 pOPINM 6-His-MBP- 0.8 1.4 2.5 0.9 1.1 0.7 
8 pOPINTF 6-His-Trigger Factor- 0.5 1.1 1.7 0.3 0.6 0.5 
9 pOPINNusA 6-His-NusA- 0.6 1.2 1.1 0.7 0.8 0.1 
Empirical scores of soluble fraction yield in small-scale expression relative to 6-His-
hCNTF construct
6
. 
                                                 
5
 Images of the SDS-PAGE gels used for the estimation of the ratio of soluble to total protein are presented in 
APPENDIX 9. 
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Empirical scores of soluble fraction yield in small-scale affinity purification relative to 6-
His-hCNTF.Affinity purified soluble fractions were analyzed by SDS-PAGE (Figure 7). 
The intensity of the bands was compared to estimate the relative amounts of soluble 
hCNTF with respect to the 6-His-construct in each condition (Table 7). Band intensity 
depends on concentration and also on the size and residue content of the protein. The 
empirical scores should therefore be used as estimates for easy summarization of results 
from small-scale screening experiments and not for direct comparisons of protein yield. 
Efficacy of the fusion tags (scores averaged over six expression conditions) was ranked; the 
trend followed MsyB / Halo (1.9-  fold); SUMO / Trx (1.6-fold); MBP / TF / NusA 
(approx. 1-fold) and GST (0.5 fold). For some of the larger fusion constructs (Figure 7; 
Halo, MBP, TF), presence of lower molecular weight fragments hinted at possible 
proteolysis. In a recent publication, similar observations was made and attributed to 
improper folding of the larger fusion constructs (Bird 2011). A noteworthy observation of 
the small-scale screening experiment was that under all conditions of expression tested, 6-
His-hCNTF constructs showed appreciable expression. It is highly desirable to be able to 
express soluble recombinant proteins without solubility enhancing ‘tags’ as downstream 
purification processes can avoid additional steps of tag cleavage and protease removal. 
Also, artifacts of low protein solubility after ‘tag’ removal can be avoided. The 6-His-tag is 
an affinity tag to aid purification and does not have solubility enhancing property. In fact, a 
study on 20 human proteins reported that 6-His-tags are known to have a negative impact 
on protein solubility when present at either the N- or C-terminus (Woestenek et al. 2004). 
This fact reinforces the notion that soluble expression of hCNTF in E. coli can be attributed 
to codon optimization. In this context, it is worthwhile to mention that in studies reported 
earlier (Masiakowski et al. 1991, McDonald et al. 1991, Negro et al. 1991, Wagener et al. 
2014), conditions of expression as varied (soluble tags, lower temperatures, expression 
strain rich in tRNAs for rare codons) as in our experimental set up were not explored. It 
seems both translation (low yields 5 – 10 mg/L) and folding (inclusion body formation) 
were limiting factors in the earlier studies. Expression studies of the wild type sequence in 
                                                                                                                                                    
6
 Images of the SDS-PAGE gels used for the comparison of soluble fraction yield in small-scale expression 
relative to 6-His-hCNTF construct are presented in APPENDIX 8 
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a strain rich in tRNAs for rare codons or with soluble fusion tags would be of interest to see 
if soluble expression of hCNTF could be achieved. Even if a positive outcome from such 
experiments were to be expected, our results with the codon-optimized sequence still 
presents a significant improvement when comparing the results of expression in BL21 at 
37° C. In our experimental set up, we achieved close to 90 % soluble fraction of hCNTF 
with the codon optimized sequence but without the aid of soluble fusion tags as compared 
to less than 20 % with the wild type sequence under similar conditions (BL21/ 37° C) 
reported in previous studies (McDonald et al. 1991, Negro et al. 1991, Masiakowski et al. 
1991, Wagener et al. 2014). Synthetic genes are easy options nowadays and our results 
present an ideal option of recombinant hCNTF production in BL21 (common laboratory 
expression strain) without a soluble fusion tag. 
 
(a) 
 
(b) 
 
(c) 
 (d) 
 
(e) 
 
(f) 
 Figure 7. SDS-PAGE analysis of affinity purification from small-scale expression 
screen. (a) BL21/20°C/PPB; (b) BL21/25°C/TBONEX; (c) BL21/37°C/PPB; (d) Rosetta 
2/20°C/PPB; (e) Rosetta 2/25°C/TBONEX; (f) Rosetta 2/37°C/PPB. Lanes M and 1 - 9 
denote protein marker and soluble Ni-NTA purified hCNTF from expression constructs as 
listed in Table 7, respectively. 
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4.4 Large scale protein expression and purification 
 
As a representative example of large scale protein production, 6-His-hCNTF was chosen 
for expression in Rosetta 2(pLysS) using auto-inducing media (TBONEX) at 25° C. Our 
choice was based on results from small scale expression screen with considerations of the 
following factors: (a) preferable construct without a soluble fusion tag to avoid additional 
tag cleavage and protease removal steps (b) high soluble yield and purity (c) easy 
experimental set up; such as, using auto-inducing media that does not require adding 
external inducing agent (Studier and Moffatt 1986). 
 
 
Figure 8. Batch IMAC purification of hCNTF. Lanes M and 1 - 6 denote protein marker 
and representative elution fractions from the resin Ni-IDA. 
 
hCNTF was extracted from cytosol by cell lysis and subjected to batch purification using 
Ni-IDA resin followed by size exclusion chromatography (SEC). Results of purification are 
depicted in Figures 8 and 9. 
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(a) (b) 
 
 
Figure 9. (a) Chromatogram of SEC-purification of hCNTF. The red line portrays the 
conductivity curve, while the blue line depicts the UV absorbance monitored at 280 nm; (b) 
SDS-PAGE analysis of hCNTF purification. M denotes protein marker and lanes 1 - 4 
represent total cell lysate, soluble protein fraction, Ni-IDA purified and SEC purified 
hCNTF, respectively. 
 
After final purification, 112 mg/L of hCNTF was obtained. This marks a significant 
improvement in overall yield as compared to previous reports of 5 – 10 mg/L 
(Masiakowski et al. 1991, McDonald et al. 1991, Negro et al. 1991, Wagener et al. 2014). 
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4.5 Functional activity assay of hCNTF 
 
 
Figure 10. Binding of biotinylated hCNTF to hCNTFRα 
 
In vitro binding assay of bCNTF to hCNTFRα was carried out to assess functionality of the 
soluble recombinant hCNTF produced in E. coli. Biotinylated hCNTF bound hCNTFRα 
with an EC50 value of 36 nM (Figure 10), in agreement with a previous report (Saggio et al. 
1994).  
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5 CONCLUSIONS 
 
We report here successful expression of high yielding soluble hCNTF in E. coli. Our 
strategy of codon optimization and factorial screening of expression conditions with nine 
soluble tags identified several conditions for soluble hCNTF expression. Soluble expression 
and yield achieved was significantly higher (8 – 9 fold) and (10 – 20 fold), respectively as 
compared to earlier studies. Soluble expression of 6-His-hCNTF in all the conditions tested 
hint to the fact that codon optimization was a sufficient criteria for soluble expression in E. 
coli. Our strategy to combine codon optimization with factorial screening might be useful 
to produce proteins of pharmaceutical relevance in E. coli.  
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 APPENDIX 1 – Preparation of E. coli competent cells 
 
Competent E. coli bacterial cells were prepared according to a protocol adopted from an 
article by Bird (Bird 2011). NEB Turbo competent E. coli and NEB 5-alpha colonies were 
grown on a lysogeny broth (LB) agar plate for approximately 9 hours at 37°C. A single 
colony was subsequently used to inoculate 5 ml of 2X LB culture medium grown overnight 
at 37°C with shaking at 220 rpm. BL21(DE3)pLysS and Rosetta 2 cells were grown on LB 
agar plates supplemented with chloramphenicol overnight at 37°C. Single colonies were 
used to inoculate 5 ml of 2x LB culture medium supplemented with chloramphenicol and 
subsequently incubated for 14 hours at 37°C with shaking at 220 rpm. 
 
1 ml of the overnight culture was used to inoculate 100 ml of 2X LB media (1:100). 
Culture media for growing BL21(DE3)pLysS and Rosetta 2 strains were supplemented 
with chloramphenicol. Cultures were grown at 37°C with shaking at 220 rpm until the 
OD600 had reached a value 0.25 - 0.3. The cultures were then cooled on ice bath for 5 min, 
divided into two 50 ml fractions and centrifuged at 4000 rpm at 4°C for 7 min. The 
supernatants were discarded. The pellets were gently re-suspended in 5 ml of 
Transformation buffer I (Tfb I, Table 8) and centrifuged at 4000 rpm at 4°C for 7 min. 
After discarding the supernatants, the pellets were re-suspended in 10 ml of Tfb I and 
incubated on ice for 5 min. After incubation, cell suspensions were centrifuged at 4000 rpm 
at 4°C for 7 min. The supernatants were discarded and the pellets gently re-suspended in 1 
ml of Transformation buffer II (Tfb II, Table 9) and incubated on ice for 15 min. The 
suspensions were flash frozen in liquid nitrogen and stored as 50 µl aliquots at -80°C. 
 
 Table 8: Composition of Tfb I 
Compound Concentration 
Potassium acetate (KOAc) 30 mM 
Rubidium chloride (RbCl) 100 mM 
Calcium chloride (CaCl2) 10 mM 
Manganese chloride (MnCl2) 50 mM 
Hexammine cobalt chloride 3 mM 
Glycerol 15 % 
pH adjusted to 5.8 with 0.2 M acetic acid and sterilized by filtration (0.22 µm) 
 
 
Table 9: Composition of Tfb II 
Compound  Concentration 
MOPS 10 mM 
Calcium chloride (CaCl2) 75 mM 
Rubidium chloride (RbCl2) 10 mM 
Glycerol 15 % 
pH adjusted to 6.5 with KOH and sterilized by filtration (0.22 µm) 
 
  
 APPENDIX 2 – Bacterial transformation 
 
Frozen E. coli competent cells were thawed on ice and as soon as the last trace of ice 
disappeared, 1 - 10 ng of DNA was added and gently mixed with the cells. The cells were 
incubated on ice for 40 min. After incubation, a heat-shock was given to the cells at 42°C 
for 30 seconds and immediately transferred to an ice bath to incubate for 5 min. After 
cooling, 800 µl of SOC (Super Optimal broth with Catabolite repression) medium was 
added to the cells and incubated at 37°C with shaking at 220 rpm for 60 min. After 
incubation, 200 µl of cell culture was pipetted and spread evenly onto a LB plate 
(supplemented with appropriate antibiotics) and incubated overnight (12 - 14 h) at 37°C. To 
increase the efficiency of colony formation, some cell cultures were centrifuged at 4°C at 
4000 rpm for 10 minutes and 600 µl of the supernatant was discarded. The cells were re-
suspended in 200 µl of media and plated to grow overnight (12 - 14 h) at 37°C. 
  
 APPENDIX 3 – Plasmid DNA purification 
 
Single separate transformed cell colonies were used to inoculate 5 ml of LB medium 
(supplemented with ampicillin) and grown overnight at 37°C with shaking at 220 rpm. 
Plasmid DNA purifications were performed using Wizard® Plus SV Minipreps DNA 
Purification System (Promega). 
 
After the overnight cultures had reached an OD600 value between 2 and 4, they were 
centrifuged at 4000 rpm (4°C) for 10 min. After centrifugation, the supernatants were 
discarded and the pellets re-suspended in 250 µl of Cell Resuspension Buffer and 
transferred to sterile 1.5 ml eppendorf tubes. 250 µl of Cell Lysis Solution was added, 
gently mixed and incubated at RT for 5 min. After incubation, 10 µl of Alkaline Protease 
Solution was added, gently mixed and incubated at RT for 5 min. To neutralize the protease 
activity, 350 µl of Neutralization buffer was added, gently mixed and centrifuged at 14,000 
g (RT) for 10 minutes. 
 
The supernatants were carefully transferred (without disturbing the debris from cell lysis) 
to spin columns and centrifuged at max speed (RT) for 1 min. The flow-through was 
discarded. 750 µl of Column Wash Solution was added to each spin column and 
centrifuged at max speed (RT) for 1 min. After discarding the flow-through, the washing 
step was repeated with 250 µl of Column Wash Solution. After centrifugation, the spin 
columns were transferred to sterile 1.5 ml eppendorf tubes and centrifuged at max speed for 
2 min. The spin columns were then transferred to sterile 1.5 ml eppendorf tubes and 70 µl 
of pre-warmed Nuclease Free Water (NFW) was added to each spin column and allowed to 
stand for 2 min. The spin columns were then centrifuged at max speed for 2 min. To 
increase the extraction efficiency, the filtrate was applied to the spin column followed by 
centrifugation. The filtrate was recovered and stored at  -20°C. 
 
 Plasmids were purified with a yield ranging roughly from 50 ng/µl to 80 ng/µl. To assess 
the purity and size of the isolated plasmids, gel electrophoresis was performed on a 1x 
TAE, 0.7 % agarose (Bionordika) gel containing 0.5 mg/ml of ethidium bromide. DNA 
samples were prepared to contain approx. 25 ng of purified plasmid DNA in the loading 
volumes of 5 µl. 
  
 APPENDIX 4 – Plasmid DNA digestion 
 
The purified pOPIN plasmids were digested with HindIII-HF™ (New England BioLabs) 
and KpnI-HF™ (New England BioLabs) restriction enzymes. Depending on the vector, 3 
µg to 3.5 µg of each plasmid DNA was used in a total digestion reaction volume of 100 µl. 
The amount of restriction enzymes was adjusted to 10 units per 1 µg of vector DNA. The 
reaction mixture was incubated at 37°C for 3.5 h. The reaction products were analyzed by 
gel electrophoresis (1x TAE, 0.7 % agarose, Bionordika) containing 0.5 mg/ml of ethidium 
bromide. DNA samples were prepared with 1 µl of reaction mixture diluted 6-fold. 5µl of 
each sample were loaded to the gel. 
  
 APPENDIX 5 – Gel extraction and purification 
 
Linearized vectors and PCR-amplified inserts were purified using a NucleoSpin ® Gel and 
PCR Clean-up (Macherey-Nagel) kit. After the electrophoretic runs, agarose slices 
containing bands of DNA were excised and weighed. Buffer NTI was added to each sample 
and subsequently allowed to incubate at 50°C for 10 min with intermittent vortex to 
dissolve the gel slices. After dissolution, 700 µl of sample was loaded to each clean-up 
column and centrifuged at 11,000 g for 30 s after which the flow-throughs were discarded. 
Remaining samples were loaded onto the clean-up columns and the centrifugation step 
repeated. 
 
700 µl of Buffer NT3 was added to each clean-up column as a wash. The samples were 
subsequently centrifuged at 11,000 g for 30 s and the flow-through discarded. The washing 
step was repeated. The samples were incubated at 70°C for 5 min and subsequently 
centrifuged at 11,000 g for 1 min to remove the Buffer NT3 and to dry the silica membrane. 
The flow-throughs were subsequently discarded. 
 
The clean-up columns were placed into new eppendorf tubes. 25 µl of preheated 0.5 X 
Buffer NE was added to each column and incubated at 70°C for 5 min and subsequently 
centrifuged at 11,000 g for 1 min. This was repeated twice with 25 µl of fresh 0.5 X Buffer 
NE to increase the recovery yield. The concentration of the isolated DNA sample was 
measured by UV spectrophotometer. 
  
 APPENDIX 6 – Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
 
1 Casting the gels 
 
For sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), 12% gels 
were cast. The resolving gels were casted first, consisting of 30% acrylamide/Bis (37.5:1, 
Bio-Rad), 1.5 M Tris-HCl pH 8.8, 10% SDS (Bio-Rad), MilliQ water, 10% APS (Bio-Rad) 
and N,N,N’,N’-tetramethylethylenediamine (TEMED, Sigma-Aldrich). After the resolving 
gels had polymerized (30 minutes), the 4 % stacking gels were casted on top of it, 
consisting of 30% acrylamide/Bis solution, 0.5 M Tris-HCl pH 6.8, 10% SDS, MilliQ 
water, APS and TEMED. After 60 min, the gels were stored at +4º C. 
 
2 Sample buffers 
 
SDS-PAGE sample buffer was prepared as a 6 X concentrate containing 62.5 mM Tris-HCl 
pH 6.8, 2 % SDS, 3 % glycerol, 5 % β-mercaptoethanol, 0.0125 % bromophenol blue and 
stored at -20°C. 
 
3 Running the gels 
 
For SDS-PAGE, PageRuler™ Plus Prestained Protein Ladder (Thermo Scientific) and/or 
Protein Marker, Broad Range, (2 - 212 kDa, New England Biolabs) were used. The 
electrophoretic runs were carried out in discontinuous buffer system of Laemmli (Laemmli 
et al. 1970) at 180 V and 160 V, for the stacking and resolving layers, respectively. The 
samples were run till the dye front reached the bottom of the gel and the markers were 
visibly well resolved. 
 
 4 6X His tag gel staining 
 
Staining of the gels of the small-scale expression screen was carried out using Pierce™ 6X 
His Protein Tag Stain Reagent Kit (Thermo Scientific) at RT. After electrophoresis, the 
gels were washed by gently agitating with Milli-Q water for 25 minutes while changing the 
wash every 5 minutes. After washing, the gels were covered with 6xHis Tag Stain and 
gently agitated for 5 minutes. After removing the staining solution, the gels were subjected 
to another washing step with Milli-Q water followed by addition of the 6xHis Protein Tag 
Developer. The gel was gently agitated for 15 minutes. The gels were finally washed with 
Milli-Q water for 25 minutes; the wash was changed every 5 minutes.  
 
5 Documentation 
 
SDS-PAGE gels were scanned and imaged (302 nm) with a ChemiDoc™ XRS+ Molecular 
Imager® system (Bio-Rad)/ Image Lab™ software (Bio-Rad). 
 
All gels were stained with Coomassie brilliant blue R-250 solution (Bio-Rad) at RT by 
gently shaking for 60 min followed by destaining with Milli-Q for 120 min while gently 
shaking and subsequently documented. 
  
 APPENDIX 7 – Plasmid DNA purification and digestion 
 
(a) (b) 
  
Figure 11. (a) Amplified and purified pOPIN vectors; (b) HindIII-HF and KpnI-HF 
linearized pOPIN vectors. M denotes DNA marker (in bp); lanes 1-9 denote the amplified 
and Miniprep-purified plasmids pOPINF, pOPINS3C, pOPINTRX, pOPINMSYB, 
pOPINJ, pOPINHALO7, pOPINM, pOPINTF and pOPINNusA, respectively. 
 
All nine plasmid vectors were amplified and purified with a high recovery. The multiple 
bands visible for each plasmid (Figure 11a) represent different DNA conformations such 
as, circular and supercoiled DNA.  
 
Linearized plasmids (Figure 11b) were purified with gel extraction.  
 
 
 
 
 
 
 
 
 APPENDIX 8 – 6X His-stained SDS-PAGE for soluble affinity purified hCNTF constructs 
 
(a) 
 
(b) 
 
(c) 
 
(d) 
 
(e) 
 
(f) 
 
Figure 12. (a) BL21/20°C/PPB; (b) BL21/25°C/TBONEX; (c) BL21/37°C/PPB; (d) 
Rosetta 2/20°C/PPB; (e) Rosetta 2/25°C/TBONEX; (f) Rosetta 2/37°C/PPB. Lanes M and 
1 - 9 denote the protein marker and soluble Ni-NTA purified hCNTF using expression 
constructs listed in Table 7, respectively. 
 
  
 APPENDIX 9 – SDS-PAGE analysis for hCNTF constructs estimation of ratio of soluble to 
total protein 
(A) 
(I) 
 
               (II) 
 
(B) 
(I) 
 
(II) 
 
(C) 
(I) 
 
(II) 
 
Figure 13. SDS-PAGE analysis of fusion hCNTF constructs in total (T) cell lysate and 
soluble (S) fraction. (A) BL21/20°C/PPB; (B) BL21/25°C/TBONEX; (C) 
BL21/37°C/PPB. Lane M and lane groupings 1 - 9 denote the protein marker and hCNTF 
constructs. 
 (A) 
(I) 
 
(II) 
 
(B) 
(I) 
 
(II) 
 
(C) 
(I) 
 
(II) 
 
Figure 14. SDS-PAGE analysis of fusion hCNTF constructs in total (T) cell lysate and 
soluble (S) fraction. (A) Rosetta 2/20°C/PPB; (B) Rosetta 2/25°C/TBONEX; (C) Rosetta 
2/37°C/PPB. Lane M and lane groupings 1-9 denote the protein marker and hCNTF 
constructs. 
  
 APPENDIX 10 – Estimation of resin amount for optimal IMAC purification 
 
To estimate the amount of Protino® nickel iminodiacetic acid (Ni-IDA) resin (Macherey-
Nagel) necessary for optimal affinity purification, the following experiment was carried 
out. 
 
The thawed cell pellet (0.41 g) was re-suspended in lysis buffer (50 mM NaH2PO4, 300 
mM NaCl, pH 8.0; 10 mM Imidazole, 1 mM DTT and PIC). The suspension was frozen at -
80°C and subsequently thawed at 37°C. This freeze-thaw cycle was repeated twice. 
Lysonase was then added and the suspension was incubated at RT for 60 min with gentle 
agitation. The lysate was subsequently centrifuged at 14,500 g at 4°C for 50 minutes. 
 
Approximately 42 mg of Ni-IDA was weighed into a microcentrifuge tube and suspended 
in 8 bed volumes
7
 of NP-buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0; 10 mM 
Imidazole, 1 mM DTT, PIC). The suspension was mixed gently at RT for 10 minutes. The 
resin was subsequently sedimented by centrifugation at 500 g for 3 min. The supernatant 
was removed and discarded. The previous step was repeated once (washing) and the resin 
was subsequently re-suspended in 8 bed volumes of NP-buffer. The total volume of 
suspension was estimated and divided into microcentrifuge tubes in fractions 0.0303, 
0.0606, 0.1515, 0.3030 and 0.4545 of the total suspension. The fractions were centrifuged 
at 500 g and the supernatants discarded. 
 
Supernatant from the cell lysate was divided into five equal fractions;  each added to the 
different resin amounts and allowed to incubate at 4°C for 90 min with gentle agitation. 
After incubation, the suspensions were centrifuged at 500 g for 3 min and the supernatants 
removed. 
 
                                                 
7
 1 g of resin corresponds to 2 ml bed volume (Macherey-Nagel) 
 Washings were carried out with 4 bed volumes of NPI-10-Tween (supplemented with 1mM 
DTT and PIC) by gently mixing for 10 min and subsequently centrifuged at 500 g for 3 
minutes. Supernatants were discarded. This step was repeated using appropriate volumes of 
NPI-25-Tween (supplemented with 1 mM DTT and PIC). 
 
Elution of bound proteins was carried out by adding 3 bed volumes of elution buffer NPI-
250-Tween (supplemented with 1 mM DTT and PIC). The suspensions were incubated at 
RT for 20 min with gentle shaking followed by centrifugation at 500 g for 3 min. The 
elution step was repeated twice and supernatants from each elution were reserved for gel 
analysis.  
 
Results 
 
  
Figure 15. SDS-PAGE analysis of small-scale IMAC purification with Ni-IDA resin. 
Lane M and lane groupings 1 - 5 denote the protein marker and Ni-IDA resin amounts of 
1.25 mg, 2.5 mg, 6.25 mg, 12.5 mg and 18.75 mg, respectively. A, B and C denote elution 
fractions. 
 
The amount of Ni-IDA resin to be used in large scale IMAC purification was decided based 
on visual inspection of SDS-PAGE analysis (Figure 15) for yield and purity. 
 
